Protein degradation targeting chimera and application thereof
By designing PROTAC molecules that target and degrade PD-L1 protein, the problems of insufficient targeting and high toxicity of existing PD-1/PD-L1 small molecule inhibitors in tumor treatment have been solved, achieving highly efficient degradation of PD-L1 protein and demonstrating broad potential for tumor treatment.
Patent Information
- Application Number
- CN202411091786.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
AI Technical Summary
Existing PD-1/PD-L1 small molecule inhibitors suffer from insufficient targeting, significant toxicity, and short half-life when treating tumors, making it difficult to effectively target undrugifiable proteins. Biphenyl compounds also have these drawbacks.
PROTAC molecules that target and degrade PD-L1 protein were designed. By combining E3 ligase ligands and linker chains with protein degradation-targeting chimeras (PROTACs), specific degradation of PD-L1 protein can be achieved, which can be applied to tumor treatment.
It achieves highly efficient targeted degradation of PD-L1 protein, and has the potential to become an anti-tumor drug, applicable to the treatment of various tumor types, including non-small cell lung cancer, colorectal cancer, gastric cancer, and cervical cancer.
Smart Images

Figure CN118994300A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of pharmacy and relates to a protein degradation targeted chimera (PROTAC) targeting PD-L1 and its medical use. Background Art
[0002] Immune checkpoint inhibitors are a class of drugs that inhibit immune system attacks by preventing tumor cells from using immune checkpoints. Immune checkpoints mainly include cytotoxic T lymphocyte-associated antigen 4, programmed cell death protein 1 (PD-1), tumor necrosis factor receptor 2, lymphocyte activation gene-3, etc. The PD-1 and its ligand, programmed death ligand 1 (PD-L1) signaling pathway, is an important regulatory mechanism in the immune system. Cancer cells often use the immune resistance mechanism of this pathway to evade the surveillance of the immune system. PD-L1 overexpressed on the surface of various tumor cells such as breast cancer, melanoma, bladder cancer and lung cancer specifically binds to PD-1 on activated T cells, inhibiting the proliferation and survival of T cells, inducing apoptosis of infiltrating T cells, and ultimately leading to T cell failure, affecting immune function, thereby supporting the survival and spread of tumor cells. PD-1 / PD-L1 inhibitors restore T cell activity and enhance immune response by blocking the specific binding between PD-1 and PD-L1. In recent years, the emergence of PD-L1 small molecule inhibitors has brought breakthroughs in tumor immunotherapy.
[0003] However, small molecule inhibitors often require higher doses and greater binding forces, and can only exert their inhibitory effects by fully binding to the target protein. However, many undruggable proteins (most transcription factors, non-enzyme proteins, and skeleton proteins, etc.) lack hydrogen bond donors and receptors, so it is impossible to effectively develop small molecule inhibitors targeting these undruggable proteins. Small molecule inhibitors have large toxic side effects, lack of targeting, and short half-life, which make them their shortcomings in cancer treatment. Targeted protein degradation technology (proteolysis targeting chimera, PROTAC) makes up for the defects of small molecule inhibitors. Unlike small molecule inhibitors that exert pharmacological effects by "occupancy drive", PROTAC molecules driven by "events" do not need to bind to the active site of the target protein, expanding the scope of druggable drugs. This has played a key role in solving undruggable target proteins and various neurodegenerative diseases associated with protein aggregation.
[0004] Biphenyl compounds have been a hot topic in the research and development of small molecule PD-L1 inhibitors in recent years. However, this type of compound has all the common disadvantages of small molecule inhibitors, such as the large toxic side effects and lack of targeting mentioned above. Therefore, how to achieve the ultimate goal of this hot method is a topic that needs further study at this stage. Summary of the invention
[0005] The purpose of the present invention is to design PROTAC molecules that target and degrade PD-L1 protein. Such PROTACs targeting PD-L1 protein can degrade PD-L1 protein, thus having the potential to be used in the treatment of tumors such as non-small cell lung cancer, colorectal cancer, gastric cancer, and cervical cancer.
[0006] The purpose of the present invention is achieved through the following technical solutions:
[0007] A protein degradation targeting chimera, the protein degradation targeting chimera is a compound composed of a target protein ligand, an E3 ligase ligand and a linker and a pharmaceutically acceptable salt thereof, and the specific structure of the compound is shown in Formula 1:
[0008]
[0009] Wherein, part A is selected from structural fragments VHL-A, VHL-B, CRBN, N-CRBN, and their structures are shown below:
[0010]
[0011] Among them, linker is selected from
[0012] n1 is an integer from 3 to 12; n2 is an integer from 0 to 5.
[0013] Preferably, the protein degradation targeting chimera is a compound represented by Formula 1 and a pharmaceutically acceptable salt thereof,
[0014] Wherein, part A is selected from structural fragments VHL-A, VHL-B, CRBN, N-CRBN, and their structures are shown below:
[0015]
[0016] In the formula, linker is selected from
[0017] n1 is 3, 4, 5, 6, 7, 8, 10 or 12; n2 is 0, 1, 2, 3 or 4.
[0018] Further preferably,
[0019] In the formula, when the A part is selected from the structural fragments VHL-A and VHL-B, in the formula, the linker is selected from
[0020] When the A part is selected from the structural fragment CRBN, the linker is selected from
[0021] When the A part is selected from the structural fragment N-CRBN, in the formula, the linker is selected from
[0022] n1 is 3, 4, 5, 6, 7, 8, 10 or 12; n2 is 0, 1, 2, 3 or 4.
[0023] More preferably, the protein degradation targeting chimera is the following compound and a pharmaceutically acceptable salt thereof,
[0024] 2.
[0025] Another object of the present invention is to provide a method for preparing the above-mentioned compound. The method for preparing the compound of formula 1 is as follows:
[0026] When the A part is selected from the structural fragments VHL-A and VHL-B,
[0027] (1) First, the VHL ligands VHL-A and VHL-B were prepared using the following route:
[0028]
[0029] The following steps are involved:
[0030] Step (1), compound Ia reacts with Boc anhydride to obtain compound Ib; step (2), compound Ib undergoes Heck coupling reaction with 4-methylthiazole to obtain compound Ic; step (3), compound Ic is subjected to removal of Boc protecting group under acidic conditions to obtain compound Id; step (4), compound Id is subjected to condensation reaction with N-Boc-L-hydroxyproline in the presence of a suitable condensing agent to obtain compound Ie; step (5), compound Ie is subjected to removal of Boc protecting group under acidic conditions to obtain compound If; step (6), compound If is subjected to condensation reaction with N-Boc-L-tert-leucine in the presence of a suitable condensing agent to obtain compound Ig; step (7), compound Ig is subjected to removal of Boc protecting group under acidic conditions to obtain VHL-A or VHL-B.
[0031] (2) Secondly, the preparation of the target protein ligand BMS-1001 adopts the following route:
[0032]
[0033] The following steps are involved:
[0034] Step (1): Compound Ih undergoes a Vilsmeier-Haack formylation reaction to obtain Compound Ii; Step (2): Compound Ij undergoes a Heck coupling reaction with 4-methylthiazole to obtain Compound Ik; Step (3): Compound Ik undergoes a Suzuki coupling reaction with benzo-1,4-dioxane-6-boronic acid to obtain Compound Il; Step (4): Compound Il undergoes a Mitsunobu reaction with 2,4-dihydroxy-5-methylbenzaldehyde to obtain Compound Im; Step (5): Compound Im undergoes a nucleophilic substitution reaction with 3-cyanobenzyl bromide to obtain Compound In; Step (6): Compound In undergoes a condensation reaction with D-serine to obtain BMS-1001.
[0035] (3) Finally, the preparation of the compound of formula 1 adopts the following route:
[0036] When linker is selected The synthetic route is as follows:
[0037]
[0038] The following steps are involved:
[0039] Step (1), in the presence of a suitable condensing agent, VHL ligand and N-Boc-aminoalkyl carboxylic acid are condensed to obtain compound Io; step (2), compound Io is deprotected from Boc protecting group under acidic conditions to obtain compound Ip; step (3), in the presence of a suitable condensing agent, compound Id is condensed with BMS-1001 to obtain a compound of formula 1.
[0040] When linker is selected The synthetic route is as follows:
[0041]
[0042] The following steps are involved:
[0043] Step (1), in the presence of a suitable condensing agent, VHL ligand and N-Boc-amino oligoethylene glycol carboxylic acid are condensed to obtain compound Iq; step (2), compound Iq is deprotected from Boc protecting group under acidic conditions to obtain compound Ir; step (3), in the presence of a suitable condensing agent, compound Ir is condensed with BMS-1001 to obtain a compound of formula 1.
[0044] When linker is selected or The synthetic route is as follows:
[0045]
[0046] The following steps are involved:
[0047] Step (1), in the presence of a suitable condensing agent, VHL ligand and cis (trans)-4-tert-butyloxycarbonylaminocyclohexanecarboxylic acid are condensed to obtain compound It; step (2), compound It is subjected to acidic conditions to remove the Boc protecting group to obtain compound Iu; step (3), in the presence of a suitable condensing agent, compound Iu is condensed with BMS-1001 to obtain a compound of formula 1.
[0048] When linker is selected The synthetic route is as follows:
[0049]
[0050] The following steps are involved:
[0051] Step (1), in the presence of a suitable condensing agent, VHL ligand and 4-Boc-1-piperazineacetic acid are condensed to obtain compound Iv; step (2), compound Iv is subjected to removal of the Boc protecting group under acidic conditions to obtain compound Iw; step (3), in the presence of a suitable condensing agent, compound Iw is subjected to condensation with N-Boc-4-aminobutyric acid to obtain compound Ix; step (4), compound Ix is subjected to removal of the Boc protecting group under acidic conditions to obtain compound Iy; step (5), in the presence of a suitable condensing agent, compound Iy is subjected to condensation with BMS-1001 to obtain a compound of formula 1.
[0052] When the A moiety is selected from the structural fragment CRBN,
[0053] When linker is selected The synthetic route is as follows:
[0054]
[0055] The following steps are involved:
[0056] Step (1), in the presence of a suitable base, compound II-a (or II-b) undergoes nucleophilic substitution with N-Boc-alkyldiamine to obtain compound II-c; step (2), compound II-c removes the Boc protecting group under acidic conditions to obtain compound II-d; step (3), in the presence of a suitable condensing agent, compound II-d undergoes condensation with BMS-1001 to obtain a compound of formula 1. When linker is selected from The synthetic route is as follows:
[0057]
[0058] The following steps are involved:
[0059] Step (1), in the presence of a suitable base, compound II-a (or II-b) undergoes nucleophilic substitution condensation with N-Boc-amino oligoethylene glycol diamine to obtain compound II-q; step (2), compound II-q removes the Boc protecting group under acidic conditions to obtain compound II-r; step (3), in the presence of a suitable condensing agent, compound II-r undergoes condensation with BMS-1001 to obtain a compound of formula I.
[0060] When linker is selected or The synthetic route is as follows:
[0061]
[0062] The following steps are involved:
[0063] Step (1), in the presence of a suitable base, compound II-a (or II-b) undergoes nucleophilic substitution with cis (or trans)-4-tert-butyloxycarbonylaminocyclohexylamine to obtain compound II-g; step (2), compound II-g is subjected to removal of the Boc protecting group under acidic conditions to obtain compound II-h; step (3), in the presence of a suitable condensing agent, compound II-h is subjected to condensation with BMS-1001 to obtain a compound of formula I.
[0064] When the A moiety is selected from the structural fragment N-CRBN,
[0065] (1) First, the CRBN ligand N-CRBN was prepared by the following route:
[0066]
[0067] The following steps are involved:
[0068] Step (1), N-Boc-4-hydroxyaniline (compound III-a) and methyl bromoacetate undergo nucleophilic substitution reaction under base catalysis to generate compound III-b; step (2), compound III-b removes the Boc protecting group under acidic conditions to obtain compound III-c; step (3), compound III-c undergoes Michael addition reaction with acrylic acid to generate compound III-d; step (4), compound III-d undergoes cyclization with urea to generate compound N-CRBN.
[0069] (2) Secondly, the preparation of the compound of formula 1 adopts the following route:
[0070]
[0071] The following steps are involved:
[0072] Step (1), in the presence of a suitable base, N-CRBN and N-Boc-alkyldiamine undergo nucleophilic substitution to obtain compound III-e; step (2), compound III-e removes the Boc protecting group under acidic conditions to obtain compound III-f; step (3), in the presence of a suitable condensing agent, compound III-f undergoes condensation with BMS-1001 to obtain a compound of formula 1.
[0073] An application of the protein degradation targeting chimera, wherein the protein degradation targeting chimera and its salt are used in protein degradation targeting PD-L1.
[0074] Use of the protein degradation targeting chimera and its salt in preparing drugs for treating PD-L1 protein related diseases.
[0075] The PD-L1 protein-related disease is a tumor or other PD-L1 protein-related disease.
[0076] The tumor is colorectal cancer, lung cancer, melanoma, bladder cancer, head and neck squamous cell carcinoma, breast cancer, prostate cancer, kidney cancer, ovarian cancer, liver cancer, pancreatic cancer, multiple myeloma.
[0077] Other PD-L1 protein-related diseases include autoimmune diseases.
[0078] A pharmaceutical composition for treating PD-L1 protein-related diseases, the composition comprising the protein degradation targeting chimera.
[0079] The compounds of the present invention can target and degrade the target protein PD-L1 and have the potential to be used as anti-tumor drugs to treat tumors; the present invention aims to explore the use of PD-L1 PROTAC molecules for tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] Figure 1 The graph shows the results of investigating the degradation of PD-L1 protein by the example compounds of the present invention in MC-38 cells. DETAILED DESCRIPTION
[0081] In order to facilitate understanding of the technical solution of the present invention, the technical solution of the present invention is clearly and completely described below through embodiments. The present invention can be implemented in many different forms, including but not limited to the embodiments described herein.
[0082] Example 1 Synthesis of VHL ligand VHL-B
[0083] (1) Synthesis of tert-butyl [(S)-1-(4-bromophenyl)ethyl]carbamate
[0084]
[0085] At room temperature, (S)-(-)-1-(4-bromophenyl)ethylamine (5 g, 25.12 mmol) was dissolved in acetone solution (40 ml), and 10% sodium hydroxide solution was added. Di-tert-butyl dicarbonate (8.23 g, 37.71 mmol) was slowly added dropwise to the mixed solution and reacted for 12 hours. The solvent was removed under reduced pressure and extracted with dichloromethane. The organic layer was dried and concentrated to obtain tert-butyl [(S)-1-(4-bromophenyl)ethyl]carbamate (5 g, 91%) as a white powder, MS m / z: 319.12 [M+Na] + .
[0086] (2) Synthesis of tert-butyl-(1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamate
[0087]
[0088] Tert-butyl [(S)-1-(4-bromophenyl)ethyl]carbamate (5g, 16.72mmol), 4-methylthiazole (3.3g, 33.33mmol), palladium acetate (75mg, 0.33mmol), potassium acetate (3.3g, 33.63mmol) were dissolved in 1,4-dioxane (30mL). The mixed solution was reacted at 80°C for 18 hours. After the reaction was completed, the mixture was filtered, extracted with dichloromethane, washed with saturated sodium chloride aqueous solution and concentrated. The residue was purified by column chromatography to obtain tert-butyl-(1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamate (3.72g, 70%), a yellow solid powder, MS m / z: 319.12 [M+H] + .
[0089] (3) (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-2-amine
[0090]
[0091] Tert-butyl-(1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamate (3.72 g, 11.70 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 20 mL) and stirred at room temperature overnight. The resulting mixture was concentrated under reduced pressure to give (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-2-amine (2.48 g, 97.3%) as a yellow solid, MS (FT-ICR) m / z: 219.0953 [M+H] + .
[0092] (4) Synthesis of tert-butyl (2S,4R)-4-hydroxy-2-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carboxylate
[0093]
[0094] (S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethan-2-amine (86 mg, 0.39 mmol), Boc-L-hydroxyproline (112.51 mg, 0.49 mmol), N,N-diisopropylethylamine (157.31 mg, 1.22 mmol), HATU (185.11 mg, 0.49 mmol) were added to N,N-dimethylformamide (15 ml) and stirred at room temperature for 8 min. h, the reaction solution was diluted with water, extracted with ethyl acetate, the organic layer was washed with water and brine, dried and concentrated, and the residue was purified by column chromatography to obtain (2S,4R)-4-hydroxy-2-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carboxylic acid tert-butyl ester (110 mg, 65%) as a yellow solid, MS (FT-ICR) m / z: 432.1950 [M+H] + .
[0095] (5) (2S,4R)-4-Hydroxy-N-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide
[0096]
[0097] Tert-butyl (2S,4R)-4-hydroxy-2-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carboxylate (110 mg, 0.26 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4M, 3 mL), and the mixture was stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure to give (2S,4R)-4-hydroxy-N-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (82 mg, 97.6%) as a yellow solid. MS (FT-ICR) m / z: 332.05 [M+H] + .
[0098] (6) Synthesis of tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoylpyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate
[0099]
[0100] A mixture of (2S,4R)-4-hydroxy-N-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (134 mg, 0.4 mmol), N-Boc-L-tert-leucine (84.23 mg, 0.36 mmol), N,N-diisopropylethylamine (156.6 mg, 1.21 mmol) and HATU (230.8 mg, 0.61 mmol) was stirred in 1,4-dioxane (30 ml) at 40°C for 5 h. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography to give tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoylpyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (187 mg, 85%) as a yellow solid. MS m / z: 567.2622 [M+Na] + .
[0101] (7) Synthesis of VHL-B:
[0102]
[0103] Tert-butyl ((S)-1-((2S,4R)-4-hydroxy-2-((R)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoylpyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (187 mg, 0.34 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 3 mL), and stirred at room temperature overnight. The reaction solution was concentrated under reduced pressure to give VHL-B (148 mg, 97%) as a yellow solid. MS m / z: 445.2280 [M+H] + . 1 H NMR (600MHz, CD3OD) δ 8.95 (s, 1H), 7.44 (d, J = 4.44Hz, 4H), 5.01-4.99 (m, 1H), 4.68 (t, J = 12.12Hz, 1H), 4.47 (s, 1H), 4.05 (s, 1H), 3.81-3.78 (d, J = 16.38Hz,1H),3.67(d,J=16.5Hz,1H),3.35(d,J=22.98Hz,2H),2.48(s,3 H),2.30-2.26(m,1H),1.98-1.92(m,1H),1.52-1.50(m,3H),1.14(s,9H). 13C NMR (151MHz, CD3OD) δ172.95,168.59,156.70,152.23,148.04,142.46,141.09,137.56,136.42,130.73,130.03,128. 25,122.24,71.11,60.75,60.44,58.14,55.91,50.31,43.87,39.03,35.78,26.70,22.46,18.78,17.34,13.22,13.07.
[0104] Example 2 Synthesis of VHL ligand VHL-A
[0105]
[0106] Prepared using the same method as VHL-B with (S)-(-)-1-(4-bromophenyl)methylamine as starting material, MS m / z: 431.18 [M+H] + . 1 H NMR (600MHz, CD3OD) δ10.03(s,1H),7.59(q,J=26.64,11.82Hz,4H),4.69(t,J=12.66Hz,1H),4.59-4.55(m,2H),4.43(d,J=23.58Hz,1H),4 .08(s,1H),3.89(d,J=16.68Hz,1H),3.73(d,J=16.62Hz,1H),3.65(s,1H),2.62(s,3H),2.34-2.29(m,1H),2.11-2.06(m,1H),1.13(s,9H). 13 C NMR (151MHz, CD3OD) δ174.09,168.70,152.92,149.10,140.27,133.43,131.60,130.42,128.98,7 1.22,61.05,60.43,58.11,55.90,43.86,43.74,39.10,35.83,26.71,18.78,17.34,15.84,13.21.
[0107] Example 3 Synthesis of CRNB ligand N-CRBN
[0108] (1) Synthesis of methyl 2-(4-((tert-butoxycarbonyl)amino)phenoxy)acetate
[0109]
[0110] N-Boc-4-hydroxyaniline (5 g, 23.90 mmol) and methyl bromoacetate (4.02 g, 26.28 mmol) were dissolved in acetone (100 ml), triethylamine (2.65 g, 26.27 mmol) and potassium iodide (39.7 mg, 0.24 mmol) were added, and the mixed solution was stirred at room temperature for 4 hours. The solvent was removed under reduced pressure and diluted with water, extracted with dichloromethane, and the organic layer was washed with water and brine, dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure to obtain methyl 2-(4-((tert-butoxycarbonyl)amino)phenoxy)acetate (5.38 g, 80%) as a pink powder, MS m / z: 304.1 [M+Na] + .
[0111] (2) Synthesis of methyl (4-aminophenoxy)acetate
[0112]
[0113] 2-(4-((tert-butoxycarbonyl)amino)phenoxy)acetic acid methyl ester (5.38 g, 19.14 mmol) was added to hydrochloric acid / 1,4-dioxane solution (4M, 15 mL) and stirred at room temperature for 8 hours. The reaction solution was concentrated under reduced pressure to give (4-aminophenoxy)acetic acid methyl ester (3.39 g, 97.6%) as a yellow solid. MS m / z: 182.0 [M+H] + .
[0114] (3) Synthesis of 3,3'-((4-(2-methoxy-2-oxyethoxy)phenyl)azadiyl)dipropionic acid
[0115]
[0116] Methyl (4-aminophenoxy)acetate (5 g, 27.61 mmol) and acrylic acid (6.92 g, 96.08 mmol) were dissolved in dichloromethane (60 ml) and refluxed with stirring for 2 hours. The solvent was removed under reduced pressure and the residue was purified by column chromatography to obtain 3,3'-((4-(2-methoxy-2-oxyethoxy)phenyl)azepinediyl)dipropionic acid (5.84 mg, 65%) as a white solid. MS m / z: 326.1 [M+H] + .
[0117] (4) Synthesis of N-CRBN
[0118]
[0119] 3,3'-((4-(2-methoxy-2-oxyethoxy)phenyl)azepinediyl)dipropionic acid (1.6 g, 4.92 mmol) and urea (443 mg, 7.38 mmol) were dissolved in N,N-dimethylformbutyramide (10 ml) and stirred at 60°C for 8 hours. After removing the solvent under reduced pressure, 1M hydrochloric acid solution (15 ml) was added and stirred at room temperature for 1 hour. After filtration, the solid was collected to obtain N-CRBN (1.04 g, 80%), a white solid, MS m / z: 262.8 [MH] - . 1 H NMR (600MHz, DMSO-d6) δ13.01 (s, 1H), 10.31 (s, 1H), 7.24 (d, J = 9Hz, 2H), 6.9 2(d,J=9Hz,2H), 4.68(s,2H), 3.71(t,J=6.66Hz,2H), 2.69(t,J=6.66Hz,2H). 13 C NMR (151MHz, DMSO-d6) δ170.72,170.23,155.75,152.35,135.39,126.85,114.49,64.63,44.91,31.12.
[0120] Example 4 Synthesis of target protein ligand BMS-1001
[0121] (1) Synthesis of 2,4-dihydroxy-5-methylbenzaldehyde
[0122]
[0123] Under ice bath conditions, 3,5-dihydroxytoluene (500 mg, 4.03 mmol) and N,N-dimethylformamide (0.63 ml) were added to acetonitrile (7 ml), phosphorus oxychloride (0.46 ml) was slowly added to the above solution, stirred at 80°C for 8 hours, diluted with water, and filtered to obtain a solid. Then, the obtained solid was added to ethanol, heated under reflux until the solid was completely dissolved, left at room temperature overnight, and filtered to obtain 2,4-dihydroxy-5-methylbenzaldehyde (240 mg, 39.16%), a yellow-white powder, MS m / z: 153.0559 [M+H] + .
[0124] (2) Synthesis of 3-bromo-2-methylbenzyl alcohol
[0125]
[0126] At room temperature, 3-bromo-2-methylbenzoic acid 30 (5.0 g, 23.37 mmol) was dissolved in anhydrous THF (25 mL), and BH3 / THF solution (1 M, 35 mL) was added dropwise. The reaction mixture was stirred at room temperature for 12 hours. The mixture was poured into 1 M hydrochloric acid, extracted with ethyl acetate, and the organic phase was concentrated under reduced pressure with anhydrous sodium sulfate to obtain 3-bromo-2-methylbenzyl alcohol (4.6 g, 99%) as a colorless solid. 1 HNMR(600MHz,DMSO-d6)δ7.48(d,J=7.92Hz,1H),7.40(d,J=7.5Hz,1H),7.11( t, J=7.8Hz, 1H), 5.24 (t, J=5.46Hz, 1H), 4.53 (d, J=5.46Hz, 2H), 2.31 (s, 3H).
[0127] (3) Synthesis of (3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylphenyl)methanol
[0128]
[0129] Benzo-1,4-dioxane-6-boronic acid (190.88 mg, 1.06 mmol), 3-bromo-2-methylbenzyl alcohol (200 mg, 1 mmol), XPhos Pd G2 (22.03 mg, 0.028 mmol), potassium phosphate (506 mg, 2.39 mmol) were dissolved in dioxane (5 ml), the mixture was purged with nitrogen, refluxed for 12 hours, the reaction solution was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain (3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylphenyl)methanol (204.91 mg, 80%) as a white solid, MS m / z: 279.0993 [M+Na] + .
[0130] (4) Synthesis of 5-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-hydroxy-5-methylbenzaldehyde
[0131]
[0132] At room temperature, 2,4-dihydroxy-5-methylbenzaldehyde (89.05 mg, 0.59 mmol), PPh3 (133.14 mg, 0.508 mmol), (3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylphenyl)methanol (100 mg, 0.39 mmol) were dissolved in anhydrous tetrahydrofuran solution (3 mL), and protected with nitrogen. DIAD ( 118.43 mg, 0.586 mmol) was dissolved in anhydrous tetrahydrofuran (3 mL) and added dropwise to the above reaction solution. The reaction solution was stirred at room temperature overnight and concentrated to dryness under reduced pressure. The residue was purified by column chromatography to obtain 5-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-hydroxy-5-methylbenzaldehyde (105.11 mg, 69%) as a white solid. MS m / z: 391.1538 [M+H] + .
[0133] (5) Synthesis of 3-((5-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-formyl-4-methylphenoxy)methyl)benzonitrile
[0134]
[0135] 5-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-hydroxy-5-methylbenzaldehyde (241 mg, 0.62 mmol), 3-cyanobenzyl bromide (172.22 mg, 0.88 mmol), triethylamine (112 mg, 1.11 mmol) were added to acetone (10 ml) and stirred at room temperature for 6 hours. The mixture was diluted with water and extracted with dichloromethane. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to give 3-((5-(3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-formyl-4-methylphenoxy)methyl)benzonitrile (265.25 mg, 85%) as a white solid. MS m / z: 528.1791 [M+H] + .
[0136] (6) Synthesis of BMS-1001
[0137]
[0138] 3-((5-(3-(2,3-dihydrobenzo[b][1,4]dioxane-6-yl)-2-methylbenzyl)oxy)-2-formyl-4-methylphenoxy)methyl)benzonitrile (305 mg, 0.6 mmol), D-serine (234.64 mg, 2.23 mmol), sodium cyanoborohydride (178.31 mg, 2.84 mmol) were added to N,N-dimethylformamide solution (15 ml), refluxed and stirred for 8 hours, the mixture was concentrated under reduced pressure, water was added, and dichloromethane was extracted. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain BMS-1001 (143.5 mg, 40%) as a white solid. MS m / z: 595.2439 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ8.03(s,1H),7.93(d,J=7.8Hz,1H),7.82(d,J=7.56Hz,1H),7.60(t,J=7.8Hz,1H),7.42(d ,J=7.38Hz,1H),7.23(t,J=7.62Hz,1H),7.17(t,J=6.6Hz,2H),6.93-6.92(m,2H),6.79(d,J=2.04Hz,1H),6.77(d d,J=8.22,2.1Hz,1H),5.29(d,J=8.46Hz,2H),5.14(s,2H),4.28(s,4H),4.09(d,J=12.96Hz,1H),4.02(d,J=13.0 2Hz,2H),3.77(dd,J=10.68,3.54Hz,1H),3.66(dd,J=11.22,6.84Hz,1H),3.17(m,1H),2.22(s,3H),2.10(s,3H). 13 CNMR(151MHz,DMSO-d6)δ168.25,157.36,155.38,142.86,142.40,141.53 ,138.55,135.41,134.33,133.73,132.76,132.41,131.61,130.97,129.6 3,129.48,127.27,125.37,122.03,118.62,117.84,117.63,116.68,111. 39,98.28,68.74,68.62,64.00,63.98,62.03,60.14,45.06,15.75,15.17. Example 5 Synthesis of Compound VA-C3-B1
[0139] (1) Synthesis of compound VA-C3-Boc
[0140]
[0141] VHL-A (300 mg, 0.697 mmol), 4-(tert-butylcarbonyl)aminobutyric acid (118.04 mg, 0.581 mmol), N,N-diisopropylethylamine (300.44 mg, 2.325 mmol), HATU (220.96 mg, 0.581 mmol) were added to N,N-dimethylformamide (5 ml) and stirred at room temperature for 4 h. The mixture was diluted with water and extracted with dichloromethane. The organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The retentate was purified by column chromatography to obtain compound VA-C3-Boc (378.5 mg, 80%) as a white solid.
[0142] MS m / z:638.2993[M+Na] + .
[0143] (2) Synthesis of compound VA-C3
[0144]
[0145] VA-C3-Boc (300 mg, 0.49 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL), stirred at room temperature overnight, and the reaction solution was concentrated to dryness under reduced pressure to obtain VA-C3 (243.71 mg, 97%) as a white solid. MS m / z: 516.2 [M+H] + .
[0146] (3) Synthesis of compound VA-C3-B1
[0147]
[0148] VA-C3 (104.05 mg, 0.20 mmol), BMS-1001 (100 mg, 0.17 mmol), N,N-diisopropylethylamine (51.6 mg, 0.40 mmol), HATU (91.3 mg, 0.24 mmol) were added to N,N-dimethylformamide (5 ml) and stirred at room temperature for 8 hours. After the solvent was removed under reduced pressure, the mixture was diluted with water and extracted with dichloromethane. The organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography to obtain VA-C3-B1 (30 mg, 13.61%) as a white solid. MS m / z: 1114.4 [M+Na] + . 1H NMR(600MHz,CD3OD)δ8.85(s,1H),7.89(s,1H),7.79(d,J=7.68Hz,1H),7.69(d,J=7.56Hz,1H),7.56(t,J=7.68Hz,1H),7.45(d,J=8.1Hz,2H),7.40-7.39(m,2H),7.34(d,J=7.32Hz,1H),7.18(t,J=7.56Hz,1H),7.15(d,J=7.26Hz,1H),7.10(s,1H),6.87(d,J=8.1Hz,1H),6.75(s,1H),6.73-6.70(m,2H),5.22(s,2H),5.11(s,2H),4.60(s,1H),4.55-4.49(m,3H),4.35(d,J=15.42Hz,1H),4.27(s,5H),3.96-3.95(m,2H),3.90(d,J=10.98Hz,1H),3.79-3.78(m,2H),3.67(s,1H),3.45(s,1H),3.22-3.11(m,2H),2.45(s,3H),2.22(s,3H),2.15(s,3H),1.78-1.70(m,2H),1.29-1.28(m,2H),1.02(s,9H),0.98(s,2H)。 13C NMR(151MHz,CD3OD)δ175.47,175.17,174.47,173.21,172.41,159.32,157.20,152.87,149.0 7,144.68,144.25,143.86,140.44,140.30,136.94,136.56,135.32,134.03,133.45,133.25, 132.85,132.18,131.56,130.98,130.89,130.87,130.52,130.41,129.47,129.02,128.89,128.58,128.56,126.54,123.43,120.54,119.68,119.18,117.93,113.78,99.37,71.15,70.54,7 0.52,69.10,65.76,65.73,62.33,60.89,59.23,58.05,57.80,57.66,57.51,57.37,52.19,48.37,48.36,48.35,48.35,48.34,48.32,48.32,47.52,43.74,39.85,38.98,37.47,36.58,35. 02,33.87,33.11,30.88,30.79,30.67,30.51,30.37,28.15,27.14,27.10,27.04,26.97,26.83,26.76,23.78,17.58,17.45,17.33,17.20,17.07,16.44,16.42,15.85,15.75,15.72,14.49.
[0159] Example 6 Synthesis of Compound VA-C4-B1
[0160]
[0161] Prepared by the same method as compound VA-C3-B1, white solid, MS m / z: 1106.7 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.86(s,1H),8.84(s,1H),7.91(s,1H),7.79(d,J=7.8Hz,1H),7.70(d,J=7.74Hz,1H),7.56(t,J=7.8Hz,1H),7.45(d,J=8.1Hz,2H),7.40(d,J=8.16Hz,2H),7.34(d,J=7.08Hz,1H),7.18(t,J=7.56Hz,1H),7.15(d,J=7.32Hz,1H),7.11(s,1H),6.87(d,J=8.16Hz,1H),6.77(s,1H),6.73-6.70(m,2H),5.23(s,2H),5.13(s,2H),4.60(s,1H),4.56-4.53(m,1H),4.50-4.47(m,2H),4.35(d,J=15.48Hz,1H),4.27(s,5H),4.03-4.00(m,2H),3.88(d,J=11.1Hz,1H),3.81-3.78(m,2H),3.70(dd,J=11.34,6.48Hz,1H),3.51(t,J=5.22Hz,1H),3.19(dd,J=13.26,6.48Hz,1H),3.13-3.09(m,1H),2.45(s,3H),2.27(t,J=7.62Hz,2H),2.23(s,3H),2.16(s,3H),2.09-2.05(m,1H),1.60(q,J=14.88,7.56Hz,2H),1.49(q,J=13.98,6.96Hz,2H),1.28(s,1H),1.01(s,9H)。 13CNMR(151MHz,CD3OD)δ175.65,174.48,172.39,159.57,157.32,152.88,149.08,144.69,144.26, 143.89,140.36,140.31,136.88,136.55,135.34,134.20,133.44,133.26,132.89,132.21,131.57 ,131.02,130.87,130.54,130.41,129.47,129.03,128.59,126.56,123.43,120.64,119.67,119.18,117.94,113.82,99.31,71.13,70.55,65.76,65.74,63.31,62.49,60.88,59.05,58.03,57.66, 57.52,57.38,48.35,48.34,48.33,48.33,48.32,48.31,48.30,48.30,48.29,48.28,48.27,48.27,48.26,48.25,48.24,48.24,48.23,48.22,48.21,48.21,48.20,48.19,48.18,48.18,48.17,48. 16,48.15,48.15,48.14,48.13,48.12,48.12,48.11,48.09,47.37,43.74,39.95,38.98,36.61,36.00,29.82,27.09,27.04,24.10,17.58,17.45,17.33,17.20,17.07,16.44,15.90,15.85,15.75.
[0162] Example 7 Synthesis of Compound VA-C5-B1
[0163]
[0164] Prepared by the same method as compound VA-C3-B1, white solid, MS m / z: 1121 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.85(s,1H),8.42(s,1H),7.91(s,1H),7.79(d,J=7.86Hz,1H),7.70(d,J=7.74Hz,1H),7.56(t,J=7.74Hz,1H),7.46(d,J=8.16Hz,2H),7.40(d,J=8.28Hz,2H),7.34(d,J=6.72Hz,1H),7.18(t,J=7.56Hz,1H),7.15(d,J=6.3Hz,1H),7.11(s,1H),6.87(d,J=8.1Hz,1H),6.77(s,1H),6.73-6.70(m,2H),5.23(s,2H),5.13(s,2H),4.61(s,1H),4.57-4.54(m,1H),4.51-4.48(m,2H),4.35(d,J=15.42Hz,1H),4.27(s,4H),4.02(s,2H),3.89(d,J=11.16Hz,1H),3.82-3.77(m,2H),3.70(dd,J=11.34,6.6Hz,1H),3.53(t,J=5.04Hz,1H),3.17-3.07(m,2H),2.45(s,3H),2.28-2.24(m,2H),2.23(s,3H),2.16(s,3H),2.09-2.05(m,1H),1.60-1.56(m,2H),1.44(t,J=8.04Hz,2H),1.30(t,J=7.5Hz,2H),1.01(s,9H)。 13C NMR(151MHz,CD3OD)δ175.84,174.50,172.40,159.70,157.37,157.02,152.88,149.07,144.69,144.68,144.26,144.24,143.89,140.31,137.09,136.85,136.60,136.54,135.33,134.56,134.24,133.45,133.31,133.26,132.91,132.21,132.12,131.56,131.02,130.96,130.89,130.56,130.41,129.40,129.02,128.58,126.56,123.46,123.43,120.69,119.66,119.20,119.17,117.94,113.84,113.79,99.51,99.29,71.13,70.57,70.55,70.11,66.19,65.76,65.73,63.17,62.33,60.88,60.86,59.04,58.05,57.66,57.52,57.38,57.23,50.18,50.14,50.12,50.10,50.09,50.08,50.08,50.07,50.06,50.05,50.04,50.03,50.02,50.02,50.01,50.00,49.99,49.99,49.98,49.97,49.96,49.96,49.95,49.94,49.93,49.93,49.92,49.91,49.90,49.90,49.89,49.88,49.87,49.87,49.86,49.85,49.84,49.84,49.83,49.82,49.81,49.81,49.80,49.79,49.78,49.78,49.77,49.76,49.75,49.75,49.74,49.73,49.72,49.72,49.71,49.61,48.31,48.30,48.29,48.29,48.28,48.27,48.26,48.26,48.25,48.24,48.23,48.23,48.22,48.21,48.20,48.20,48.19,48.18,48.17,48.17,48.16,48.15,48.14,48.14,48.13,48.12,48.11,48.11,48.10,48.09,48.08,48.08,48.07,48.06,48.05,48.05,48.04,48.03,48.02,48.02,48.01,48.00,47.99,47.99,47.98,47.97,47.96,47.96,47.95,47.94,47.93,47.92,47.91,47.90,47.90,47.89,47.88,47.87,47.87,47.85,47.84,47.83,47.82,47.81,47.81,47.80,47.79,4 7.78,47.77,47.76,47.74,47.72,47.29,43.74,40.38,39.76,38.98,37.56,36.59,36.56,36.48,30.24,30.01,27.54,27.44,27.08,27.04,26.64,26.57,17.58,17.45,17.33,17.20,17.07,16.51,16.44,15.90,15.85,15.78,15.75. .
[0165] Example 8 Synthesis of Compound VA-C7-B1
[0166]
[0167] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1149.2 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.85(s,1H),8.43(s,1H),7.91(s,1H),7.79(d,J=7.38Hz,1H),7.70(d,J=7.62Hz,1H),7.57(t,J=7.8Hz,1H),7.46(d,J=8.16Hz,2H),7.40(d,J=8.22Hz,2H),7.34(d,J=7.38Hz,1H),7.19(t,J=7.56Hz,1H),7.16(d,J=7.62Hz,1H),7.11(s,1H),6.88(d,J=8.16Hz,1H),6.76(s,1H),6.73-6.71(m,2H),5.23(s,2H),5.13(s,2H),4.62(s,1H),4.57-4.51(m,2H),4.48(s,1H),4.35(d,J=15.42Hz,1H),4.27(s,4H),4.02(s,2H),3.89(d,J=10.5Hz,1H),3.80-3.78(m,2H),3.68(m,1H),3.52(s,1H),3.13-3.07(m,2H),2.46(s,2H),2.26(d,J=7.74Hz,1H),2.23(s,3H),2.21-2.19(m,1H),2.16(s,3H),2.09-2.05(m,1H),1.57(q,J=13.02,6.9Hz,2H),1.41(t,J=6.78Hz,2H),1.29(s,6H),1.01(s,9H),0.98(s,1H)。 13C NMR(151MHz,CD3OD)δ176.02,174.50,172.39,159.70,157.38,152.88,149.08,144.69,144.26,143.89,140.32,137.09,136.85,136.54,135.31,134.24,133.46,133.30,133.24,132.90,132.19,132.09,131.56,131.02,130.96,130.89,130.55,130.41,129.02,128.55,126.57,123.43,120.67,119.65,119.20,119.18,117.95,113.85,99.27,71.12,70.57,70.53,70.47,65.77,65.74,63.18,62.39,62.17,60.89,58.99,58.07,57.81,57.66,57.52,57.37,57.23,50.49,50.48,50.47,50.44,50.43,50.42,50.42,50.41,50.40,50.39,50.39,50.38,50.37,50.36,50.35,50.34,50.33,50.33,50.32,50.31,50.30,50.30,50.29,50.28,50.27,50.27,50.26,50.25,50.24,50.24,50.23,50.22,50.21,50.21,50.20,50.19,50.18,50.18,50.17,50.16,50.15,50.15,50.14,50.13,50.12,50.12,50.11,50.10,50.09,50.09,50.08,50.07,50.06,50.06,50.05,50.04,50.03,50.03,50.02,50.01,50.00,50.00,49.99,49.98,49.97,49.97,49.96,49.95,49.94,49.94,49.93,49.92,49.91,49.91,49.90,49.89,49.88,49.88,49.87,49.86,49.85,49.85,49.84,49.83,49.82,49.82,49.81,49.80,49.79,49.79,49.78,49.77,49.76,49.76,49.75,49.74,49.73,49.73,49.72,49.71,48.36,48.35,48.34,48.33,48.33,48.32,48.31,48.30,48.30,48.29,48.28,48.27,48.27,48.26,48.25,48.24,48.24,48.23,48.22,48.21,48.21,48.20,48.19,48.18,48.18,48.17,48.16 ,48.15,48.15,48.14,48.13,48.12,48.12,48.11,48.10,48.09,48.09,48.08,48.07,48.06,48.06,48.05,48.04,48.03,48.03,48.02,48.01,48.00,48.00,47.99,47.98,47.97,47.97,4 7.96,47.95,47.94,47.94,47.93,47.92,47.91,47.91,47.90,47.89,47.88,47.88,47.87,47.86,47.85,47.85,47.84,47.83,47.82,47.82,47.81,47.32,43.74,40.52,39.82,38.98,36. 64,36.63,36.48,35.04,30.48,30.29,30.22,30.15,30.03,29.99,27.76,27.72,27.13,27.08,26.90,26.86,17.58,17.45,17.33,17.20,17.08,16.50,16.44,15.86,15.78,15.76,15.74. .
[0168] Example 9 Synthesis of Compound VA-C9-B1
[0169]
[0170] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1176.3 [M+H] + . 1H NMR(600MHz,CD3OD)δ7.91(s,1H),7.85(d,J=7.74Hz,1H),7.73(d,J=7.68Hz,1H),7.61(t,J=7.8Hz,1H),7.40(d,J=7.32Hz,1H),7.23(t,J=7.56Hz,1H),7.20(d,J=7.38Hz,1H),7.08(s,1H),6.93(d,J=8.16Hz,1H),6.79-6.78(m,2H),6.76-6.75(m,2H),5.23(s,2H),5.14(s,2H),4.36(s,1H),4.32(s,5H),3.80-3.74(m,2H),3.73(s,3H),3.71(d,J=4.86Hz,1H),3.60(dd,J=10.8,7.08Hz,1H),3.24(dd,J=6.84,5.04Hz,1H),3.14(t,J=7.14Hz,2H),2.32-2.29(m,2H),2.28(s,4H),2.20(s,3H),1.61(t,J=6.84Hz,3H),1.45(t,J=6.3Hz,2H),1.34-1.31(m,18H),1.07(s,1H),1.03(s,9H)。 13C NMR (151MHz, CD3OD) δ176.40,176.06,174.75,174.49,173.17,172.38,158.32,156.85,152. 86,144.67,144.22,143.80,140.87,140.32,137.18,136.63,135.23,133.46,133.39,133.15 ,132.70,131.99,131.55,130.89,130.87,130.84,130.40,129.01,128.50,126.51,123.45,120.78,120.08,119.67,119.19,117.92,113.72,99.49,71.12,70.50,70.35,65.75,65.73,65 .12,64.20,62.14,60.86,58.99,58.06,57.52,52.14,48.38,48.37,48.36,48.35,48.35,48.34,48.32,48.30,48.15,43.74,40.18,38.95,36.71,36.63,36.58,35.05,33.11,30.88,30.7 9,30.77,30.69,30.67,30.64,30.58,30.55,30.50,30.39,30.37,30.31,30.28,28.15,28.01,27.13,27.09,27.06,26.97,23.78,17.45,17.33,17.20,16.43,16.42,15.86,15.77,14.49.
[0171] Example 9 Compound VA-C 11 Synthesis of -B1
[0172]
[0173] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1205.2 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.86(s,1H),8.43(s,1H),7.91(s,1H),7.80(d,J=7.86Hz,1H),7.70(d,J=7.74Hz,1H),7.57(t,J=7.74Hz,1H),7.46-7.45(m,2H),7.41(t,J=6.48Hz,2H),7.34(d,J=7.38Hz,1H),7.19(t,J=7.56Hz,1H),7.15(d,J=8.76Hz,1H),7.11(s,1H),6.88(d,J=8.1Hz,1H),6.76(s,1H),6.73-6.70(m,2H),5.24(s,2H),5.12(s,2H),4.62(s,1H),4.57-4.54(m,2H),4.52-4.49(m,2H),4.37-4.33(m,1H),4.27(s,4H),4.02(d,J=7.02Hz,1H),3.90(d,J=10.98Hz,1H),3.81-3.79(m,2H),3.68(dd,J=11.28,6.72Hz,1H),3.52(t,J=4.74Hz,1H),3.09(t,J=7.14Hz,2H),2.46(s,3H),2.29-2.26(m,1H),2.23(s,3H),2.16(s,3H),2.10-2.05(m,1H),1.91(s,1H),1.59-1.55(m,3H),1.47(t,J=5.4Hz,1H),1.39(t,J=6.6Hz,2H),1.30(s,4H),1.25(s,8H),1.02(s,9H)。 13C NMR(151MHz,CD3OD)δ176.11,176.07,174.51,174.49,173.19,172.39,159.65,157.37,152.87,149.07,144.69,144.26,1 43.87,140.36,140.33,140.32,136.86,136.53,135.26,134.22,133.46,133.27,133.22,132.88,132.17,132.07,131.55, 130.99,130.94,130.88,130.53,130.41,129.44,129.01,128.50,128.40,126.56,123.45,123.43,120.62,119.64,119.21,119.18,117.94,113.84,99.26,71.12,70.56,70.50,70.40,70.14,69.11,66.25,65.76,65.74,63.31,62.46,61.16,60.8 7,60.86,58.99,58.28,58.06,57.66,57.51,57.37,48.34,48.34,48.33,48.32,48.31,48.31,48.30,48.29,48.29,48.28,48.27,48.26,48.26,48.25,48.24,48.23,48.23,48.22,48.21,48.20,48.19,48.18,48.17,47.42,43.73,41.33,40.56,39 .88,38.95,37.54,36.73,36.71,36.65,36.62,30.72,30.69,30.68,30.65,30.63,30.62,30.49,30.47,30.45,30.40,30.36,28.04,27.99,27.88,27.09,27.07,27.05,22.56,17.45,17.33,17.20,16.51,16.45,15.88,15.86,15.84,15.79,15.76.
[0174] Example 10 Synthesis of Compound VB-C3-B1
[0175]
[0176] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1106.30 [M+H] +。 1 HNMR(600MHz,CD3OD)δ8.86(s,1H),8.42(s,1H),7.91(s,1H),7.80(d,J=7.92Hz,1H),7.70(d,J=7.74Hz,1H),7.57(t,J=7.8Hz,1H),7.43(p,J=16.44,8.4Hz,4H),7.34(d,J=7.98Hz,1H),7.18(t,J=7.62Hz,1H),7.15(d,J=7.2Hz,2H),6.87(d,J=8.16Hz,1H),6.78(s,1H),6.73-6.70(m,2H),5.24(s,2H),5.13(s,2H),4.99(d,J=7.02Hz,1H),4.62(s,1H),4.59-4.54(m,2H),4.42(s,1H),4.26(s,4H),4.07(s,2H),3.87-3.83(m,2H),3.76-3.72(m,2H),3.59(s,1H),3.24-3.19(m,1H),3.16-3.11(m,1H),2.46(s,3H),2.30-2.25(m,2H),2.22(s,3H),2.16(s,3H),1.97-1.92(m,1H),1.77-1.70(m,2H),1.49(d,J=7.08Hz,3H),1.03(s,9H)。 13C NMR(151MHz,CD3OD)δ175.12,174.31,173.22,172.73,172.59,172.36,169.92,168.7 0,159.77,157.36,152.89,152.83,149.10,146.09,145.65,144.67,144.24,143.86,1 40.26,140.20,136.83,136.78,136.52,136.50,135.32,134.31,133.37,133.33,133.27,132.90,132.33,132.23,131.56,131.43,131.01,130.88,130.53,130.49,128.57, 127.65,127.44,126.56,123.42,120.73,119.67,119.65,119.17,117.93,113.80,99.28,71.02,70.58,70.53,69.07,65.74,65.72,63.04,62.11,60.81,60.63,59.26,58.5 5,58.02,56.32,50.46,50.16,47.19,41.23,39.97,38.84,37.56,36.50,34.06,33.85,30.71,27.12,27.07,26.75,22.71,22.42,16.45,15.88,15.84,15.75,15.65,13.84.
[0177] Example 11 Synthesis of Compound VB-C4-B1
[0178]
[0179] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1120.90 [M+H] + . 1HNMR(600MHz,CD3OD)δ8.86(s,1H),8.44(s,1H),7.91(s,1H),7.80(d,J=7.8Hz,1H),7.70(d,J=7.74Hz,1H),7.56(t,J=7.74Hz,1H),7.43(q,J=15.66,8.4Hz,4H),7.34(d,J=6.6Hz,1H),7.18(t,J=7.56Hz,1H),7.14(d,J=6.12Hz,2H),6.87(d,J=8.16Hz,1H),6.77(s,1H),6.73-6.70(m,2H),5.24(s,2H),5.12(s,2H),5.00(q,J=13.92,6.96Hz,1H),4.59-4.54(m,2H),4.41(s,1H),4.26(s,4H),4.05(s,2H),3.85-3.82(m,2H),3.73(dd,J=10.86,4.14Hz,2H),3.57(s,1H),3.22-3.17(m,1H),3.14-3.11(m,1H),2.46(s,3H),2.28(t,J=7.02Hz,2H),2.22(s,3H),2.16(s,3H),1.97-1.92(m,1H),1.60-1.54(m,3H),1.49(d,J=7.02Hz,4H),1.01(s,9H)。 13C NMR(151MHz,CD3OD)δ175.63,174.91,173.23,172.73,172.61,172.33,159.76,159.65,15 7.33,152.88,152.82,149.09,146.07,145.65,144.66,144.23,143.85,140.30,140.21,1 36.84,136.80,136.51,135.31,134.25,133.36,133.31,133.25,132.88,132.20,131.55,131.45,131.00,130.86,130.52,130.49,128.56,127.65,127.43,126.56,123.42,120.70, 120.66,119.67,119.17,117.93,113.79,99.27,70.99,70.55,70.52,69.08,65.73,65.71,63.21,63.12,62.33,62.17,60.79,60.61,59.08,59.06,58.45,57.99,57.50,56.34,50. 48,50.16,49.61,47.27,47.19,41.23,39.95,38.82,37.61,36.51,36.48,36.34,35.96,30.71,29.79,29.58,27.10,27.07,24.45,24.07,22.75,22.40,16.45,15.91,15.84,15.76.
[0184] Example 12 Synthesis of Compound VB-C5-B1
[0185]
[0186] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1135.00 [M+H] + . 1HNMR(600MHz,CD3OD)δ8.86(s,1H),8.46(s,1H),7.90(s,1H),7.79(d,J=7.92Hz,1H),7.70(d,J=7.74Hz,1H),7.56(t,J=7.8Hz,1H),7.43(q,J=14.7,8.4Hz,4H),7.34(d,J=7.08Hz,1H),7.18(t,J=7.62Hz,1H),7.14(d,J=7.38Hz,1H),7.11(s,1H),6.87(d,J=8.1Hz,1H),6.76(s,1H),6.73-6.70(m,2H),5.24(s,2H),5.12(s,2H),5.01(q,J=13.92,6.9Hz,1H),4.60(s,1H),4.56(t,J=8.34Hz,1H),4.41(s,1H),4.26(s,4H),3.98(d,J=3.36Hz,1H),3.87(d,J=11.1Hz,1H),3.81(dd,J=11.34,4.68Hz,1H),3.74(dd,J=10.98,3.96Hz,1H),3.69(dd,J=11.16,6.6Hz,1H),3.49(t,J=5.76Hz,1H),3.16-3.08(m,2H),2.46(s,3H),2.29-2.24(m,2H),2.22(s,3H),2.16(s,3H),1.97-1.91(m,1H),1.61-1.55(m,3H),1.49(d,J=7.02Hz,3H),1.46(dd,J=15.06,7.38Hz,2H),1.33-1.28(m,2H),1.02(s,9H)。 13C NMR(151MHz,CD3OD)δ175.82,173.24,172.79,172.61,172.34,170.89,169.35,159.40,1 57.25,157.21,152.88,152.79,149.09,149.03,146.11,145.66,144.66,144.23,143.83 ,140.39,140.30,136.90,136.87,136.52,136.51,135.28,134.07,133.37,133.29,133.23,132.86,132.15,131.54,131.45,130.98,130.86,130.52,130.49,128.54,127.65,12 7.41,126.55,123.42,120.54,119.66,119.17,117.93,116.04,113.78,99.31,71.00,70.52,69.11,65.73,65.71,63.55,62.68,60.80,60.61,59.06,58.36,58.01,56.36,50.50 ,50.15,47.46,41.22,40.40,40.30,38.82,37.64,36.84,36.48,36.46,30.71,30.04,27.54,27.43,27.26,27.10,27.07,26.78,26.58,22.84,22.42,16.44,15.93,15.84,15.76.
[0197] Example 13 Synthesis of Compound VB-C7-B1
[0198]
[0199] Prepared by the same method as compound VA-C3-B1, white solid. MS m / z: 1163.05 [M+H] + . 1HNMR(600MHz,CD3OD)δ8.86(s,1H),8.47(s,1H),7.89(s,1H),7.79(d,J=7.8Hz,1H),7.69(d,J=7.74Hz,1H),7.56(t,J=7.8Hz,1H),7.43(q,J=14.16,8.46Hz,4H),7.34(d,J=6.84Hz,1H),7.18(t,J=7.62Hz,1H),7.14(d,J=7.56Hz,1H),7.10(s,1H),6.87(d,J=8.1Hz,1H),6.75(s,1H),6.73-6.70(m,2H),5.22(s,2H),5.11(s,2H),5.01(q,J=13.98,6.96Hz,1H),4.61(s,1H),4.56(t,J=8.4Hz,1H),4.41(s,1H),4.26(s,4H),3.96(s,2H),3.87(d,J=11.1Hz,1H),3.80(dd,J=11.28,4.68Hz,1H),3.74(dd,J=11.04,3.9Hz,1H),3.67(dd,J=11.16,6.72Hz,1H),3.47(t,J=4.98Hz,1H),3.13-3.08(m,2H),2.46(s,3H),2.28-2.24(m,1H),2.22(s,3H),2.16(s,3H),1.96-1.92(m,1H),1.59-1.55(m,2H),1.49(d,J=7.02Hz,3H),1.41(t,J=6.9Hz,2H),1.9(s,7H),1.02(s,9H)。 13C NMR(151MHz,CD3OD)δ176.00,175.16,173.25,172.55,172.33,159.35,157.23, 152.88,152.84,149.09,146.10,145.67,144.66,144.23,143.83,140.43,136. 91,136.52,135.25,134.04,133.37,133.20,132.84,132.12,131.54,131.41,130.97,130.86,130.51,128.51,127.65,127.47,126.55,123.43,120.51,119.6 6,119.17,117.93,113.78,99.30,70.98,70.50,69.08,65.73,65.71,63.63,62.79,60.82,60.61,59.00,58.34,58.03,56.28,50.43,50.15,47.52,41.17,40. 42,38.81,37.63,37.01,36.60,36.52,30.71,30.32,30.21,30.16,30.10,30.01,27.79,27.77,27.09,26.89,26.87,22.71,22.43,16.44,15.88,15.84,15.77.
[0206] Example 14 Synthesis of Compound VA-P1-B1
[0207] (1) Synthesis of VA-P1-Boc
[0208]
[0209] VHL-A (500 mg, 1.16 mmol), 5-tert-butoxycarbonylamino-3-oxavalanic acid (212.34 mg, 0.97 mmol), N,N-diisopropylethylamine (500.74 mg, 3.87 mmol), HATU (552.4 mg, 1.45 mmol) were added to dichloromethane (5 ml) and stirred at room temperature for 4 h. The mixture was diluted with water and extracted with dichloromethane. The organic phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain VA-P1-Boc (378.5 mg, 52%) as a white solid. MS m / z: 654.3 [M+Na] + .
[0210] (2) Synthesis of VA-P1
[0211]
[0212] VA-P1-Boc (378.5 mg, 0.6 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL), stirred at room temperature overnight, and the reaction solution was concentrated under reduced pressure to obtain VA-P1 (308.9 mg, 97%) as a white solid. MS m / z: 532.3 [M+H] + .
[0213] (3) Synthesis of compound VA-P1-B1
[0214]
[0215] VA-P1 (159 mg, 0.30 mmol), BMS-1001 (148.2 mg, 0.25 mmol), N,N-dimethylaminopyridine (50.45 mg, 0.50 mmol), EDCI (57.37 mg, 0.30 mmol), HOBT (40.44 mg, 0.30 mmol) were added to N,N-dimethylformamide (5 ml) and stirred at room temperature for 4 h. After removing the solvent, the mixture was diluted with water (50 ml) and extracted with dichloromethane (3×50 ml). The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The desired VA-P1-B1 (30 mg, 10%) was prepared by high performance liquid chromatography as a white solid. MS m / z: 1108.7 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.83(s,1H),8.42(s,1H),7.90(s,1H),7.78(d,J=7.86Hz,1H),7.69(d,J=7.74Hz,1H),7.55(t,J=7.8Hz,1H),7.42(d,J=7.92Hz,2H),7.38(d,J=8.28Hz,2H),7.33(d,J=6.72Hz,1H),7.18(t,J=7.56Hz,1H),7.15(d,J=6.54Hz,1H),7.12(s,1H),6.87(d,J=8.16Hz,1H),6.76(s,1H),6.72-6.70(m,2H),5.22(s,2H),5.12(s,2H),4.69(s,1H),4.55(t,J=7.92Hz,1H),4.49(s,1H),4.47(d,J=15.24Hz,1H),4.35(d,J=15.48Hz,1H),4.27(s,4H),4.03(d,J=3.6Hz,2H),3.96(d,J=15.12Hz,1H),3.85-3.80(m,2H),3.74(dd,J=11.4,6.42Hz,1H),3.60-3.58(m,2H),3.53-3.50(m,1H),3.46-3.42(m,1H),3.34-3.32(m,1H),2.43(s,3H),2.22(s,4H),2.15(s,4H),2.10-2.06(m,1H),1.01(s,9H)。 13C NMR (151MHz, CD3OD) δ174.31,172.00,171.70,170.98,159.64,157.36,152.95,152.87,149. 09,144.68,144.67,144.26,144.23,143.88,140.30,140.23,139.88,136.85,136.80,136.5 3,135.36,135.34,134.30,133.39,133.31,133.24,132.93,132.89,132.81,132.31,132.22,131.62,131.02,130.87,130.57,130.44,129.49,129.03,129.00,128.93,128.59,126.56,1 23.45,123.43,120.68,119.68,119.17,117.94,113.83,113.82,99.28,71.16,71.06,70.92,70.76,70.56,70.54,69.09,65.76,65.73,63.09,62.26,61.00,58.22,58.13,57.66,57.52 ,57.38,56.44,49.61,48.32,47.21,44.41,43.77,41.43,40.45,40.33,39.03,37.74,37.27,37.13,27.05,27.00,26.96,17.45,17.33,17.20,17.07,16.56,16.46,15.88,15.87,15.77.
[0227] Example 15 Synthesis of Compound VA-P2-B1
[0228]
[0229] Prepared by the same method as compound VA-P1-B1. MS m / z: 1152.35 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.48(s,1H),7.86(s,1H),7.78(d,J=7.68Hz,1H),7.67(d,J=7.62Hz,1H),7.54(t,J=7.74Hz,1H),7.42(d,J=8.16Hz,2H),7.39(d,J=8.22Hz,2H),7.33(d,J=7.32Hz,1H),7.17(t,J=7.56Hz,1H),7.14(d,J=7.5Hz,1H),7.03(s,1H),6.87(d,J=8.1Hz,1H),6.73-6.70(m,3H),5.18(s,2H),5.08(s,2H),4.71(s,1H),4.57(t,J=8.04Hz,1H),4.51-4.49(m,2H),4.34(d,J=15.36Hz,1H),4.26(s,4H),3.96(d,J=5.58Hz,1H),3.92(d,J=15.84Hz,1H),3.87-3.84(m,1H),3.81-3.78(m,2H),3.67-3.63(m,4H),3.60-3.55(m,4H),3.51(t,J=5.16Hz,2H),3.42-3.38(m,1H),2.44(s,3H),2.22(s,3H),2.13(s,3H),2.10-2.06(m,1H),2.03(s,2H),1.02(s,9H)。 13C NMR(151MHz,CD3OD)δ174.33,172.15,171.80,158.47,156.86,152.87,1 49.09,144.67,144.23,143.80,140.74,140.26,137.12,136.60,135.28 ,133.59,133.41,133.20,132.72,132.13,132.07,131.59,130.90,130. 83,130.55,130.42,129.49,129.07,129.04,128.56,128.09,126.52,123 .44,120.17,119.72,119.18,117.92,117.90,116.20,113.70,99.48,72.31,71.18,71.06,70.95,70.68,70.51,70.35,65.75,65.73,64.72,63. 78,60.93,58.22,58.14,57.52,49.61,48.07,44.41,43.79,40.21,39.00,37.81,37.27,27.04,17.33,16.47,16.44,15.90,15.89,15.79,15.77.
[0240] Example 16 Synthesis of Compound VA-P3-B1
[0241]
[0242] Prepared by the same method as compound VA-P1-B1. MS m / z: 1197.05 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.48(s,1H),8.40(s,1H),7.91(s,1H),7.79(d,J=7.86Hz,1H),7.69(d,J=7.74Hz,1H),7.56(t,J=7.74Hz,1H),7.44(d,J=8.22Hz,2H),7.39(d,J=8.22Hz,2H),7.34(d,J=7.38Hz,1H),7.18(t,J=7.56Hz,1H),7.15-7.13(m,2H),6.87(d,J=8.16Hz,1H),6.77(s,1H),6.73-6.70(m,2H),5.23(s,2H),5.13(s,2H),4.68(s,1H),4.56(t,J=7.8Hz,1H),4.51-4.48(m,2H),4.36(d,J=15.42Hz,1H),4.26(s,4H),4.09-4.04(m,2H),4.01(d,J=5.34Hz,2H),3.86-3.82(m,2H),3.80(dd,J=10.98,3.72Hz,1H),3.73(dd,J=11.46,6.42Hz,1H),3.66-3.60(m,8H),3.58-3.56(m,2H),3.48-3.42(m,2H),2.45(s,3H),2.22(s,4H),2.16(s,3H),2.10-2.06(m,1H),1.02(s,9H)。 13C NMR (151MHz, CD3OD) δ174.37,172.08,171.75,159.74,157.38,152.94,152. 88,149.08,144.68,144.25,143.87,140.27,139.89,136.83,136.51,135.33 ,134.35,133.42,133.27,132.90,132.27,132.25,131.57,131.03,130.87,130.56,130.42,129.51,129.02,128.58,126.57,123.43,120.74,120.70,119 .68,119.17,117.94,113.82,99.26,72.20,71.73,71.70,71.58,71.37,71.34,71.14,71.09,70.56,70.53,70.39,69.10,65.75,65.73,63.04,62.18,61 .07,60.89,58.17,58.16,57.98,56.42,49.61,47.16,44.40,43.76,41.39,40.53,39.02,37.73,37.16,27.02,26.99,17.33,16.47,15.89,15.88,15.78.
[0252] Example 17 Synthesis of Compound VA-P4-B1
[0253]
[0254] Prepared by the same method as compound VA-P1-B1. MS m / z: 1241.15 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.84(s,1H),8.41(s,1H),7.91(s,1H),7.79(d,J=7.86Hz,1H),7.69(d,J=7.74Hz,1H),7.56(t,J=7.8Hz,1H),7.44-7.42(m,2H),7.39(d,J=8.28Hz,2H),7.34(d,J=7.38Hz,1H),7.18(t,J=7.56Hz,1H),7.15-7.13(m,2H),6.87(d,J=8.16Hz,1H),6.77(s,1H),6.73-6.70(m,2H),5.23(s,2H),5.13(s,2H),4.67(s,1H),4.56(t,J=9Hz,1H),4.52-4.48(m,2H),4.35(d,J=15.48Hz,1H),4.26(s,4H),4.07-4.04(m,2H),4.01(d,J=5.7Hz,2H),3.86-3.82(m,2H),3.79(dd,J=10.98,3.72Hz,1H),3.73(dd,J=11.4,6.48Hz,1H),3.66-3.65(m,2H),3.63-3.62(m,3H),3.60-3.59(m,5H),3.57-3.55(m,2H),3.54-3.53(m,2H),3.47-3.45(m,2H),2.45(s,3H),2.22(s,4H),2.16(s,3H),2.09-2.05(m,1H),1.02(s,9H)。 13C NMR(151MHz,CD3OD)δ174.37,172.08,171.74,171.33,170.09,168.72,159.68,15 7.36,152.93,152.87,149.07,144.67,144.25,143.86,140.28,140.27,139.92,1 36.85,136.50,135.32,134.33,133.42,133.29,133.27,132.89,132.26,132.24,131.54,131.02,130.87,130.55,130.41,129.52,129.00,128.58,126.58,123.43 ,120.66,119.69,119.18,117.95,113.80,99.25,72.26,71.63,71.61,71.59,71.50,71.47,71.26,71.20,71.11,71.09,70.55,70.52,70.35,69.09,65.74,65.72, 63.13,62.26,61.07,60.87,58.20,58.14,57.98,56.38,47.18,44.38,43.75,41.37,40.52,40.47,39.01,37.70,37.11,27.02,26.99,16.48,15.90,15.88,15.79.
[0265] Example 18 Synthesis of Compound VA-S-B1
[0266] (1) Synthesis of compound VA-S-Boc
[0267]
[0268] VHL-A (212.18 mg, 0.49 mmol), cis-4-tert-butoxycarbonylaminocyclohexanecarboxylic acid (100 mg, 0.41 mmol), N,N-diisopropylethylamine (106.25 mg, 0.82 mmol), EDCI (94.55 mg, 0.49 mmol), HOBT (66.64 mg, 0.49 mmol) were added to N,N-dimethylformamide (3 ml) and stirred at room temperature for 4 h. After removing the solvent, the mixture was diluted with water (50 ml) and extracted with dichloromethane (3×50 ml). The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Column chromatography (dichloromethane: methanol = 8:1)
[0269] The residue was purified to give VA-S-Boc (200 mg, 62%) as a white solid. MS m / z: 678.3 [M+Na] + .
[0270] (2) Synthesis of VA-S
[0271]
[0272] VA-S-Boc (200 mg, 0.31 mmol) was added to a hydrochloric acid-1,4-dioxane solution (4 M, 5 mL), stirred at room temperature overnight, and the reaction mixture was concentrated under reduced pressure to obtain VA-S (164.4 mg, 97%) as a white solid. MS m / z: 578.3 [M+Na] + .
[0273] (3) Synthesis of compound VA-S-B1
[0274]
[0275] VA-S (150 mg, 0.27 mmol), BMS-1001 (133.76 mg, 0.23 mmol), N,N-dimethylaminopyridine (45.54 mg, 0.45 mmol), EDCI (53.51 mg, 0.28 mmol), HOBT (36.49 mg, 0.27 mmol) were added to N,N-dimethylformamide (3 ml) and stirred at room temperature for 4 h. After removing the solvent, the mixture was diluted with water (50 ml) and extracted with dichloromethane (3×50 ml). The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The desired VA-S-B1 (10 mg, 3.27%) was prepared by high performance liquid chromatography as a white solid. MS m / z: 1133.00 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.86(s,1H),8.42(s,1H),7.94(s,1H),7.81(d,J=7.8Hz,1H),7.71(d,J=7.74Hz,1H),7.57(t,J=7.74Hz,1H),7.46(d,J=8.16Hz,2H),7.41(d,J=8.22Hz,2H),7.33(d,J=7.14Hz,1H),7.18(t,J=7.56Hz,1H),7.15(d,J=7.5Hz,1H),7.11(s,1H),6.87(d,J=8.16Hz,1H),6.76(s,1H),6.73-6.71(m,2H),5.26(d,J=3.12Hz,2H),5.11(s,2H),4.62-4.61(m,1H),4.57-4.52(m,2H),4.49(s,1H),4.35(d,J=15.42Hz,1H),4.26(s,4H),4.18(d,J=13.2Hz,1H),4.07(d,J=13.2Hz,1H),3.87-3.84(m,3H),3.80(dd,J=10.92,3.84Hz,1H),3.73-3.65(m,2H),2.46(s,3H),2.42-2.38(m,1H),2.23(s,3H),2.15(s,3H),2.10-2.06(m,1H),1.67-1.54(m,8H),1.00(s,9H)。 13C NMR (151MHz, CD3OD) δ178.04,174.46,172.30,159.96,157.54,152.88,149.08,144.68,144.26,143.88,140.32,140.29,136.78,136.53,13 5.36,134.46,133.45,133.26,133.23,132.90,132.27,131.56,131.0 5,130.87,130.53,130.41,129.50,129.01,128.61,126.58,126.34,12 3.43,120.70,119.64,119.17,117.96,113.84,99.16,71.12,70.62,70.53,65.76,65.73,62.66,62.33,60.85,58.70,58.01,52.16,47.42,46.61,43.74,43.61,39.03,37.58,36.88,35.15,30.15,29.65,27.13,27.09,27.05,26.44,24.91,17.33,17.20,16.49,15.90,15.85,15.80.
[0285] Example 19 Synthesis of Compound VB-S-B1
[0286]
[0287] VB-S-B1 was prepared using the same method as VA-S-B1 using VHL-B as the E3 ligase ligand. MS m / z: 1146.90 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.87(s,1H),8.37(s,1H),7.95(s,1H),7.82(d,J=7.92Hz,1H),7.71(d,J=7.8Hz,1H),7.57(t,J=7.74Hz,1H),7.44(q,J=17.04,8.4Hz,4H),7.33(d,J=6.96Hz,1H),7.20-7.14(m,2H),7.12(s,1H),6.88(d,J=8.16Hz,1H),6.77(s,1H),6.73-6.71(m,2H),5.28(d,J=4.5Hz,2H),5.12(s,2H),5.01(q,J=13.92,6.96Hz,1H),4.60-4.54(m,2H),4.42(s,1H),4.27(s,4H),4.22(d,J=13.14Hz,1H),4.12(d,J=13.08Hz,1H),3.89-3.87(m,2H),3.84(d,J=11.1Hz,1H),3.75-3.72(m,3H),2.47(s,3H),2.42-2.39(m,1H),2.23(s,3H),2.15(s,3H),1.97-1.93(m,1H),1.77-1.74(m,1H),1.61-1.54(m,7H),1.50(d,J=7.02Hz,3H),1.01(s,9H)。 13C NMR(151MHz,CD3OD)δ178.06,173.23,172.70,172.26,168.04,160.14,157.60,152 .90,152.88,149.12,145.98,145.68,144.68,144.27,143.89,140.22,136.73,136 .52,135.35,134.56,133.38,133.26,132.92,132.28,131.79,131.57,131.07,130.87,130.53,128.60,127.65,127.47,126.59,123.42,120.78,119.63,119.17,117 .96,113.86,99.13,71.00,70.65,70.53,69.07,65.76,65.73,62.43,62.12,60.82,60.61,58.76,58.24,57.98,57.66,57.52,56.31,50.43,50.17,49.75,49.72,49. 61,47.29,46.67,43.59,41.21,38.90,37.67,36.78,30.13,29.62,27.11,27.09,26.40,24.90,22.67,22.42,17.45,17.33,17.20,16.49,15.86,15.83,15.82,15.80.
[0298] Example 20 Synthesis of Compound VA-F-B1
[0299] (1) Synthesis of compound VA-F-Boc
[0300]
[0301] VA-F-Boc was prepared by the same preparation method as VA-S-Boc, using trans-4-tert-butyloxycarbonylaminocyclohexanecarboxylic acid as the raw material. MS m / z: 678.2 [M+Na] + .
[0302] (2) Synthesis of Compound VA-F
[0303]
[0304] VA-F was prepared by the same method as compound VA-S, MS m / z: 556.3 [M+H] + .
[0305] (3) Synthesis of compound VA-F-B1
[0306]
[0307] VA-F-B1 was prepared by the same method as compound VA-S-B1. MS m / z: 1133.40 [M+H] + . 1 H NMR(600MHz,CD3OD)δ8.86(s,1H),7.92(s,1H),7.80(d,J=7.92Hz,1H),7.71(d,J=7.74Hz ,1H),7.57(t,J=7.74Hz,1H),7.47(d,J=8.22Hz,2H),7.41(d,J=8.22Hz,2H),7.33(d,J=7. 32Hz,1H),7.19(t,J=7.56Hz,1H),7.15(d,J=7.44Hz,1H),7.12(s,1H),6.87(d,J=8.1Hz, 1H),6.77(s,1H),6.73-6.70(m,2H),5.25(s,2H),5.13(s,2H),4.61(s,1H),4.57-4.53(m, 2H),4.49(s,1H),4.35(d,J=15.42Hz,1H),4.27(s,4H),4.13(dd,J=34.08,13.14Hz,2H), 3.89(d,J=11.16Hz,1H),3.83-3.79(m,2H),3.71(dd,J=11.4,6.66Hz,1H),3.55(t,J=4.8H z,2H),2.46(s,3H),2.31-2.27(m,1H),2.22(s,3H),2.16(s,3H),2.11-2.05(m,1H),1.95 -1.85(m,3H),1.79(d,J=10.92Hz,2H),1.57-1.47(m,2H),1.26-1.13(m,2H),1.02(s,9H). 13C NMR (151MHz, CD3OD) δ178.03,174.46,172.35,159.91,157.46,152.88,149.08,144.68,144.25,143.89,140.33,140.26,136.79,13 6.53,135.29,134.36,133.46,133.23,133.19,132.90,132.24,131.56,131.04,130.85,130.55,130.41,129.44,129.02,128.54,1 26.59,123.42,120.71,119.64,119.17,117.94,113.85,99.22,71.13,70.59,70.55,65.76,65.73,62.92,62.22,60.90,58.80,58.09,47.23,44.77,43.74,38.97,37.55,36.81,32.76,32.66,30.04,29.02,27.05,27.01,17.32,17.20,16.42,15.88,15.85,15.73.
[0316] Example 21 Synthesis of Compound VB-F-B1
[0317]
[0318] VB-F-B1 was prepared using the same method as VA-F-B1 using VHL-B as the E3 ligase ligand. MS m / z: 1146.95 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.86(s,1H),7.86(s,1H),7.79(d,J=7.8Hz,1H),7.68(d,J=7.62Hz,1H),7.56-7.54(m,1H),7.43-7.38(m,4H),7.34(d,J=7.14Hz,1H),7.19-7.16(m,1H),7.14(d,J=7.38Hz,1H),7.03(s,1H),6.86(d,J=8.16Hz,1H),6.73-6.70(m,3H),5.17(s,2H),5.08(s,2H),5.01-4.98(m,1H),4.60-4.55(m,2H),4.42(s,1H),4.26(s,4H),3.94-3.90(m,1H),3.86(d,J=11.1Hz,1H),3.75(s,2H),3.68-3.66(m,1H),3.57-3.54(m,2H),3.22-3.20(m,1H),2.47(s,2H),2.22(s,3H),2.15(s,3H),1.97-1.92(m,1H),1.88-1.83(m,2H),1.79(d,J=12.9Hz,1H),1.50(d,J=6.96Hz,3H),1.28(s,2H),1.15(d,J=6.18Hz,6H),1.03(s,9H)。 13 C NMR(151MHz,CD3OD)δ178.09,173.34,173.23,172.29,158.51,156.90,152.87,149.09,145.68,144.65,144.20,143.77,140.74,137.10,136.58,135.22,133.47,133.37,133.18,132.71,132.04,131.54,130.90,130.88,130.80,130.52,128.50,127.64,126.53,123.44,120.14,119.68,119.18,117.92,113.68,99.39,71.00,70.51,70.35,65.73,65.70,64.77,64.71,63.99,60.62,58.81,58.04,50.15,48.02,44.77,38.79,36.69,32.86,32.76,30.77,30.36,30.09,29.08,27.07,25.29,22.44,16.42,15.84,15.78。
[0330] Example 22 Synthesis of Compound VA-PQ-B1
[0331] (1) Synthesis of compound VA-PQ-Boc
[0332]
[0333] VHL-A (400 mg, 0.93 mmol), 4-Boc-1-piperazineacetic acid (189.28 mg, 0.77 mmol), N,N-diisopropylethylamine (400.6 mg, 3.10 mmol), HATU (294.6 mg, 0.0.77 mmol) were added to N,N-dimethylformamide (3 ml) and stirred at room temperature for 4 h. After removing the solvent, the mixture was diluted with water (50 ml) and extracted with dichloromethane (3×50 ml). The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain VA-PQ-Boc (396 mg, 65%) as a white solid, MS m / z: 679.3 [M+Na] + .
[0334] (2) Synthesis of compound VA-PQ
[0335]
[0336] VA-PQ-Boc (396 mg, 0.60 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL), stirred at room temperature overnight, and the reaction mixture was concentrated under reduced pressure to obtain VA-PQ (328.96 mg, 98%) as a white solid. MS m / z: 557.2 [M+H] + .
[0337] (3) Synthesis of compound VA-PQ-C3-Boc
[0338]
[0339] VA-PQ (350 mg, 0.63 mmol), N-Boc-4-aminobutyric acid (106.55 mg, 0.52 mmol), N,N-dimethylaminopyridine (106.06 mg, 1.05 mmol), EDCI (120.6 mg, 0.63 mmol), HOBT (85 mg, 0.63 mmol) were added to N,N-dimethylformamide (3 ml) and stirred at room temperature for 4 h. After removing the solvent, the mixture was diluted with water (50 ml) and extracted with dichloromethane (3×50 ml). The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane: methanol = 8:1) to obtain the desired VA-PQ-C3-Boc (300 mg, 64%). White solid, MSm / z: 764.3 [M+Na] + .
[0340] (4) Synthesis of compounds to VA-PQ-C3
[0341]
[0342] VA-PQ-C3-Boc (444 mg, 0.60 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL) and stirred at room temperature.
[0343] Overnight, the reaction mixture was concentrated under reduced pressure to give VA-PQ-C3 (365.4 mg, 95%) as a white solid, MS m / z: 642.3 [M+H] + .
[0344] (5) Synthesis of compound VA-PQ-B1
[0345]
[0346] VA-PQ-C3 (248 mg, 0.39 mmol), BMS-1001 (191.42 mg, 0.32 mmol), N,N-dimethylaminopyridine (65.17 mg, 0.64 mmol), EDCI (74.1 mg, 0.39 mmol), HOBT (52.23 mg, 0.39 mmol) were added to N,N-dimethylformamide (3 ml) and stirred at room temperature for 4 h. After removing the solvent, the mixture was diluted with water (50 ml) and extracted with dichloromethane (3×50 ml). The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. VA-PQ-B1 (15 mg, 3.19%) was prepared by high performance liquid chromatography as a white solid. MS m / z: 1218.1 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.84(s,1H),7.94(s,1H),7.80(d,J=7.86Hz,1H),7.70(d,J=7.68Hz,1H),7.56(t,J=7.74Hz,1H),7.45(d,J=7.92Hz,2H),7.40(d,J=8.16Hz,2H),7.34(d,J=7.32Hz,1H),7.18(t,J=7.56Hz,1H),7.15-7.14(m,2H),6.87(d,J=8.16Hz,1H),6.79(s,1H),6.73-6.70(m,2H),5.25(s,2H),5.13(s,2H),4.64(s,1H),4.57(dd,J=16.86,8.94Hz,1H),4.50-4.49(m,2H),4.36(d,J=15.42Hz,1H),4.26(s,4H),4.13(d,J=6Hz,2H),3.88-3.85(m,2H),3.81-3.74(m,3H),3.65-3.64(m,1H),3.61(s,2H),3.57-3.50(m,3H),3.23-3.17(m,1H),3.15-3.10(m,1H),3.08(d,J=8.64Hz,1H),2.53-2.52(m,2H),2.49-2.48(m,2H),2.45(s,3H),2.35(t,J=7.5Hz,2H),2.22(s,3H),2.16(s,3H),2.10-2.05(m,1H),1.74-1.68(m,2H),1.03(s,9H)。 13C NMR (151MHz, CD3OD) δ174.33,173.18,171.93,160.00,157.48,152.85,149.07,144.68,144.25,143.87,140.28,140.20,13 6.80,136.50,135.31,134.46,133.42,133.27,132.93,132.27,131.58,131.03,130.87,130.58,130.41,129.52,129.05,12 8.54,126.58,123.43,120.78,119.70,119.17,117.95,113.83,99.23,71.08,70.62,70.50,65.75,65.73,61.89,61.71,60.90,58.39,58.19,54.46,54.03,46.81,43.76,42.94,40.18,39.01,37.09,31.23,27.05,27.00,26.01,16.47,15.88,15.76.
[0353] Example 22 Synthesis of Compound VB-PQ-B1
[0354]
[0355] VB-PQ-B1 was prepared using the same method as VA-PQ-B1 using VHL-B as the E3 ligase ligand. MS m / z: 1232.95 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.86(s,1H),7.94(s,1H),7.81(d,J=7.8Hz,1H),7.71(d,J=7.62Hz,1H),7.58(t,J=7.74Hz,1H),7.44(q,J=18.78,8.34Hz,4H),7.35(d,J=6.96Hz,1H),7.19(t,J=7.56Hz,1H),7.16-7.15(m,2H),6.88(d,J=8.16Hz,1H),6.79(s,1H),6.73-6.71(m,2H),5.26(s,2H),5.14(s,2H),5.01(q,J=13.92,6.96Hz,1H),4.63(s,1H),4.56(t,J=8.88Hz,1H),4.43(s,1H),4.27(s,4H),4.11(s,2H),3.87-3.84(m,2H),3.77-3.73(m,2H),3.64-3.62(m,3H),3.58-3.51(m,3H),3.23-3.20(m,1H),3.17-3.11(m,2H),3.08(d,J=12.72Hz,1H),2.53-2.52(m,2H),2.49(t,J=4.8Hz,2H),2.47(s,3H),2.38(t,J=7.32Hz,2H),2.23(s,3H),2.17(s,3H),1.97-1.92(m,1H),1.76-1.70(m,2H),1.57(d,J=7.02Hz,1H),1.50(d,J=7.08Hz,2H),1.04(s,9H)。 13C NMR (151MHz, CD3OD) δ173.22,173.13,171.96,171.90,159.95,157.47,152.89,149.12,149.11,145.67,144.69,144.26,143.88,140.23 ,136.82,136.50,135.33,134.43,134.40,133.37,133.28,132.93,1 32.28,131.58,131.03,130.89,130.54,128.56,127.65,127.45,126 .58,123.43,120.78,119.70,119.17,117.96,113.85,99.26,70.98,70.62,70.53,69.11,65.76,65.73,62.87,61.95,61.72,60.84,60.67,58.41,58.20,54.48,54.05,50.18,47.16,46.82,42.95,40.17,38.88,37.72,37.08,31.23,27.06,26.02,22.44,16.46,15.84,15.75.
[0356] Example 23 Synthesis of Compound CL-C3-B1
[0357] (1) Synthesis of compound CL-C3-Boc
[0358]
[0359] 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (200 mg, 0.72 mmol), N-tert-butyloxycarbonyl-1,3-propanediamine (151.39 mg, 0.87 mmol), cesium carbonate (357.5 mg, 1.10 mmol) were dissolved in 1,4-dioxane (3 ml) and refluxed with stirring for 8 h, cooled to room temperature, the solvent was removed and the mixture was diluted with water, extracted with dichloromethane, the organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain CL-C3-Boc (150 mg, 48.160%), yellow powder. MS m / z: 453.1 [M+Na] + .
[0360] (2) Synthesis of compound CL-C3
[0361]
[0362] CL-C3-Boc (150 mg, 0.35 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL) and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give CL-C3 (113.98 mg, 99%), a yellow liquid, MS m / z: 331.1 [M+H] + .
[0363] (3) Synthesis of compound CL-C3-B1
[0364]
[0365] CL-C3 (250 mg, 0.76 mmol), BMS-1001 (374.94 mg, 0.63 mmol), triethylamine (127.26 mg, 1.26 mmol), EDCI (145.14 mg, 0.76 mmol) were added to N, N-dimethylformamide (3 ml) and stirred at room temperature for 12 h. The reaction mixture was diluted with water, extracted with dichloromethane, and the organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated to dryness under reduced pressure. The residue was purified by preparative high performance liquid chromatography to obtain CL-C3-B1 (30 mg, 4.37%), yellow powder, MS m / z: 907.4 [M+H] + . 1H NMR(600MHz,CDCl3)δ8.18(s,1H),7.81(d,J=7.38Hz,2H),7.64(t,J=6.84Hz,1H),7.58(d,J=7.8Hz,1H),7.46-7.42(m,2H),7.33(t,J=4.56Hz,1H),7.21(d,J=4.86Hz,2H),7.04(d,J=7.44Hz,2H),6.91(d,J=8.22Hz,1H),6.84-6.81(m,2H),6.77(dd,J=8.22,1.92Hz,1H),6.50(s,1H),6.40(d,J=14.7Hz,1H),5.13(d,J=3.06Hz,2H),4.99(s,2H),4.90-4.89(m,1H),4.31(s,4H),4.07(t,J=13.32Hz,1H),4.00-3.89(m,3H),3.85-3.80(m,1H),3.73(s,1H),3.31-3.19(m,4H),2.82(d,J=12.96Hz,1H),2.70-2.68(m,2H),2.21(d,J=1.74Hz,3H),2.13(d,J=6.78Hz,3H),2.08(s,1H),1.76-1.74(m,2H),1.25(s,1H)。 13 C NMR(151MHz,CDCl3)δ171.43,169.58,169.16,167.50,158.29,155.58,146.53,143.06,142.68,142.34,138.16,138.12,136.29,135.16,135.11,135.04,133.95,133.23,133.03,132.48,131.78,131.62,130.92,130.90,130.82,130.07,129.56,129.52,127.10,125.54,124.83,122.55,119.98,119.94,118.67,118.22,116.93,116.64,112.78,111.65,110.00,97.74,97.55,69.42,69.32,64.46,64.44,62.11,61.19,52.71,48.90,47.30,43.39,40.13,40.04,37.38,31.36,29.70,28.68,22.81,16.70,16.19,16.16,15.49,15.46。
[0366] Example 24 Synthesis of Compound CL-C5-B1
[0367]
[0368] The compound was prepared using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,5-pentanediamine as raw materials by the same method as compound CL-C3-B1. MS m / z: 935.4 [M+H] + . 1 H NMR (600MHz, CD3OD) δ8.51(s,1H),7.87(s,1H),7.78(d,J=7.74Hz,1H),7.67(d,J =7.74Hz,1H),7.56-7.53(m,1H),7.49-7.46(m,1H),7.34(d,J=7.5Hz,1H),7.17(t ,J=7.74Hz,1H),7.14(d,J=7.38Hz,1H),7.03(s,1H),6.98-6.95(m,2H),6.87(d,J =8.1Hz,1H),6.73(d,J=1.92Hz,1H),6.72(dd,J=8.16,2.1Hz,1H),6.69(s,1H),5. 17(s,2H),5.09(s,2H),5.00-4.97(m,1H),4.27(s,4H),3.78(d,J=9.24Hz,1H),3 .72(dd,J=11.16,5.04Hz,1H),3.58-3.55(m,1H),3.26-3.24(m,2H),3.14(t,J=6. 54Hz,2H),2.82-2.76(m,1H),2.70-2.60(m,2H),2.22(s,3H),2.13(s,3H),2.03-1 .99(m,1H),1.64-1.61(m,2H),1.48-1.45(m,2H),1.41-1.37(m,2H),1.29(s,3H). 13C NMR (151MHz, CD3OD) δ174.65,171.68,169.32,158.67,156.98,148.24,144.68,144.24,143.82,140.69,13 7.27,137.09,136.60,135.28,133.92,133.67,133.18,132.76,132.07,130.91,130.84,128.52,126.53,1 23.45,120.22,119.69,119.19,117.92,113.73,111.82,111.04,99.39,70.48,70.41,65.76,57.66,57.52,57.38,50.22,43.26,40.02,32.24,30.14,29.92,25.24,23.82,17.45,17.33,17.20,17.07,16.44,15.76.
[0369] Example 25 Synthesis of Compound CL-C6-B1
[0370]
[0371] CL-C6-B1 was prepared using the same method as compound CL-C3-B1, using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,6-hexanediamine as raw materials. MS m / z: 949.5 [M+H] + . 1H NMR (600MHz, CD3OD) δ8.46(s,1H),7.89(s,1H),7.79(d,J=7.62Hz,1H),7.68(d,J=7.6 8Hz,1H),7.55(t,J=7.74Hz,1H),7.46(t,J=8.16Hz,1H),7.34(d,J=7.38Hz,1H),7.18( t,J=7.62Hz,1H),7.14(d,J=7.32Hz,1H),7.08(s,1H),6.99(d,J=7.02Hz,1H),6.95(d ,J=8.46Hz,1H),6.87(d,J=8.04Hz,1H),6.72-6.70(m,3H),5.20(s,2H),5.10(s,2H),5 .04(dd,J=12.54,5.64Hz,1H),4.27(s,4H),3.92(d,J=7.08Hz,2H),3.77(dd,J=11.28 ,4.74Hz,1H),3.65(dd,J=11.16,6.72Hz,1H),3.42-3.41(m,1H),3.23(t,J=7.02Hz,2H ),3.13-3.08(m,2H),2.85-2.78(m,1H),2.73-2.66(m,2H),2.22(d,J=1.62Hz,3H),2. 15(s,3H),2.08-2.04(m,1H),1.62-1.57(m,2H),1.42-1.37(m,4H),1.32-1.30(m,2H). 13 C NMR (151MHz, CD3OD) δ174.66,171.70,170.89,169.34,159.14,157.15,148.25,144.67,144.24,143.83,1 40.52,137.27,136.99,136.55,135.28,133.91,133.22,132.82,132.13,130.95,130.85,128.52,126.54 ,123.44,120.39,119.69,119.19,117.97,117.92,113.77,111.81,111.01,99.29,70.48,65.76,64.08,63.12,63.11,57.66,57.52,57.38,50.23,43.27,40.26,32.24,30.30,30.18,27.58,23.85,16.45,15.77.
[0372] Example 26 Synthesis of Compound CL-C8-B1
[0373]
[0374] CL-C8-B1 was prepared by the same method as compound CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,8-octanediamine as raw materials. MS m / z: 977.4 [M+H] + . 1 H NMR(600MHz,CD3OD)δ7.85(s,1H),7.79(d,J=7.74Hz,1H),7.67(d,J=7.74Hz,1H ),7.54(t,J=7.8Hz,1H),7.48(t,J=7.26Hz,1H),7.34(d,J=7.38Hz,1H),7.17(t, J=7.62Hz,1H),7.13(d,J=7.5Hz,1H),7.03(s,1H),6.99(d,J=7.08Hz,1H),6.95( d,J=8.58Hz,1H),6.86(d,J=8.1Hz,1H),6.72-6.68(m,3H),5.16(s,2H),5.07(s, 2H),5.03(dd,J=12.54,5.58Hz,1H),4.26(s,4H),3.71(d,J=3.06Hz,2H),3.68(d d,J=10.86,4.98Hz,1H),3.55(dd,J=10.86,7.08Hz,1H),3.22-3.17(m,3H),3.08 (t,J=6.9Hz,2H),2.84-2.78(m,1H),2.72-2.69(m,1H),2.21(s,3H),2.14(s,3H) ,2.07-2.03(m,1H),1.58(t,J=7.2Hz,2H),1.40-1.33(m,4H),1.29-1.28(m,7H). 13C NMR (151MHz, CD3OD) δ174.76,174.67,171.68,170.87,169.36,158.30,156.82,148.29,144.66,144.22,143 .77,140.84,137.25,137.18,136.59,135.20,133.92,133.36,133.17,132.71,132.01,130.84,128.46,126 .52,123.45,120.73,120.05,119.69,119.20,117.97,117.91,113.71,111.76,110.98,99.42,70.46,70.34,65.75,65.23,64.20,50.22,48.33,48.32,43.40,40.12,32.24,30.38,30.22,27.82,23.85,16.44,15.80.
[0375] Example 27 Compound CL-C 10 Synthesis of -B1
[0376]
[0377] CL-C was prepared by the same method as compound CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,10-decanediamine as raw materials. 10 -B1. MS m / z: 1005.5 [M+H] + . 1H NMR(600MHz,CD3OD)δ8.49(s,1H),7.89(s,1H),7.80(d,J=7.86Hz,1H),7.68(d,J=7.74Hz,1H),7.56(t,J=7.8Hz,1H),7.51(dd,J=8.52,7.14Hz,1H),7.34(d,J=6.66Hz,1H),7.18(t,J=7.56Hz,1H),7.14(d,J=8.82Hz,1H),7.07(s,1H),7.00(dd,J=16.74,7.02Hz,2H),6.86(d,J=8.16Hz,1H),6.73-6.70(m,3H),5.21(s,2H),5.09(s,2H),5.04(dd,J=12.24,5.34Hz,1H),4.26(s,4H),3.89(s,2H),3.76(dd,J=11.1,4.74Hz,1H),3.63(dd,J=11.1,6.9Hz,1H),3.38(t,J=5.52Hz,1H),3.24(t,J=7.02Hz,2H),3.13-3.08(m,2H),2.85-2.79(m,1H),2.73-2.67(m,2H),2.22(s,3H),2.15(s,3H),2.09-2.04(m,1H),1.60-1.57(m,2H),1.38-1.34(m,4H),1.31-1.28(m,4H),1.25(s,6H)。 13C NMR (151MHz, CD3OD) δ174.68,171.70,170.87,169.36,159.09,157.15,148.32,144 .67,144.23,143.81,140.56,137.27,136.99,136.55,135.21,133.94,133.88,133 .21,132.80,132.11,130.93,130.86,128.46,126.54,123.44,120.37,119.67,119.19,117.99,117.92,113.78,111.77,111.74,110.99,99.32,70.47,65.76,65.73,6 4.15,63.20,57.66,57.52,57.37,57.23,50.22,49.87,49.81,49.80,49.79,49.77,49.61,48.26,47.85,47.84,43.44,43.43,40.56,40.37,32.25,30.88,30.62,30. 59,30.52,30.50,30.45,30.40,30.38,30.36,30.34,30.30,30.28,28.15,28.01,27.99,27.95,27.93,23.85,22.56,17.58,17.45,17.32,17.20,17.07,16.45,15.79.
[0378] Example 28 Compound CL-C 12 Synthesis of -B1
[0379]
[0380] CL-C was prepared by the same method as compound CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,12-dodecanediamine as raw materials. 12 -B1. MS m / z: 1033.5 [M+H] + . 1HNMR(600MHz,CD3OD)δ8.48(s,1H),7.89(s,1H),7.80(d,J=7.8Hz,1H),7.69(d,J=7.68Hz,1H),7.56(t,J=7.86Hz,1H),7.51(t,J=7.38Hz,1H),7.34(d,J=7.26Hz,1H),7.18(t,J=7.5Hz,1H),7.14(d,J=7.38Hz,1H),7.08(s,1H),7.01(dd,J=11.04,7.02Hz,2H),6.87(d,J=8.1Hz,1H),6.73-6.70(m,3H),5.22(s,2H),5.10(s,2H),5.04(dd,J=12.6,5.4Hz,1H),4.26(s,4H),3.93(d,J=4.32Hz,1H),3.78(dd,J=11.22,4.74Hz,1H),3.64(dd,J=11.16,6.84Hz,1H),3.42(t,J=4.62Hz,1H),3.26(t,J=6.96Hz,2H),3.11(q,J=14.22,7.02Hz,2H),2.85-2.79(m,1H),2.74-2.67(m,2H),2.22(s,3H),2.16(s,3H),2.08-2.06(m,1H),1.61-1.59(m,2H),1.39-1.36(m,4H),1.30-1.28(m,4H),1.23(s,11H)。 13C NMR(151MHz,CD3OD)δ174.71,171.70,170.86,169.38,159.24,157.21,14 8.32,144.66,144.24,144.23,143.80,140.50,137.28,136.95,136.54,13 5.21,134.53,133.99,133.92,133.56,133.22,132.99,132.82,132.34,132.11,131.01,130.94,130.87,128.46,126.55,123.44,120.92,120.42,11 9.67,119.19,119.16,118.01,117.92,113.77,111.78,110.96,99.30,70.48,65.76,65.73,63.94,63.02,57.66,57.52,57.37,50.21,47.77,43.43, 40.43,32.24,30.63,30.61,30.58,30.51,30.41,30.35,30.31,30.29,27.98,27.96,23.84,17.44,17.32,17.19,16.53,16.46,16.39,15.79,15.64.
[0381] Example 29 Synthesis of Compound CJ-C5-B1
[0382]
[0383] CJ-C5-B1 was prepared using the same method as CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,5-pentanediamine as raw materials. MS m / z: 935.55 [M+H] + . 1H NMR(600MHz,CDCl3)δ8.23(s,1H),7.78(s,1H),7.74(s,1H),7.64(d,J=7.86Hz,1H),7.57(d,J=7.68Hz,1H),7.45(t,J=7.56Hz,2H),7.33(t,J=4.86Hz,1H),7.21(d,J=4.02Hz,1H),7.06(s,1H),6.91(d,J=8.28Hz,1H),6.84(s,1H),6.81(d,J=1.98Hz,1H),6.76(dd,J=8.22,2.04Hz,1H),6.63(d,J=8.04Hz,1H),6.51(s,1H),5.12(s,2H),4.99(s,2H),4.90(dd,J=12.06,5.4Hz,1H),4.30(s,4H),4.05(dd,J=29.94,12.3Hz,1H),3.91(s,1H),3.83-3.81(m,1H),3.72(s,1H),3.20-3.08(m,4H),2.81-2.65(m,3H),2.22(s,3H),2.12(s,3H),2.06(t,J=7.44Hz,1H),1.58(s,2H),1.45(t,J=6.48Hz,2H),1.34(t,J=6.54Hz,2H),1.25(s,1H)。 13 C NMR(151MHz,CDCl3)δ171.72,169.30,168.20,167.49,158.22,155.58,154.04,143.06,142.68,142.33,138.19,135.09,135.07,134.39,134.00,133.96,133.25,131.77,131.62,131.51,131.22,130.84,130.78,130.07,129.55,127.22,127.11,125.54,125.44,124.83,122.54,119.93,118.68,118.22,117.26,116.93,112.73,97.82,97.61,69.45,69.41,69.33,64.45,64.43,62.11,61.37,52.55,49.00,47.10,46.90,43.03,39.01,31.93,31.42,29.70,29.37,28.83,27.95,23.80,22.74,16.17,15.49,14.13。
[0384] Example 30 Synthesis of Compound CJ-C6-B1
[0385]
[0386] CJ-C6-B1 was prepared using the same method as CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,6-hexanediamine as raw materials. MS m / z: 949.55 [M+H] + . 1 H NMR (600MHz, CDCl3) δ8.27(s,1H),7.78(s,1H),7.65(d,J=7.5Hz,1H),7.58(d, J=7.68Hz,1H),7.49-7.45(m,2H),7.34(t,J=4.5Hz,1H),7.21(d,J=4.32Hz,1H ),7.06(s,1H),6.91(d,J=8.22Hz,1H),6.86(s,1H),6.80(d,J=1.92Hz,1H),6. 76(dd,J=8.22,1.92Hz,1H),6.66(d,J=8.34Hz,1H),6.51(s,1H),5.13(s,2H),4 .99(s,2H),4.90(dd,J=11.04,4.44Hz,1H),4.30(s,4H),4.04(dd,J=29.7,7.1 4Hz,1H),3.91(d,J=11.4Hz,1H),3.81-3.80(m,1H),3.68(s,1H),3.16-3.10(m, 5H),2.82-2.68(m,3H),2.22(s,3H),2.13(d,J=4.5Hz,3H),2.07(t,J=7.26Hz, 1H), 1.56 (t, J = 5.34Hz, 2H), 1.41 (s, 2H), 1.34-1.32 (m, 2H), 1.28-1.25 (m, 3H). 13C NMR (151MHz, CDCl3) δ171.66,169.19,169.17,168.18,168.16,167.70,16 7.49,167.47,158.16,157.52,155.56,153.95,143.06,142.67,142.33,1 38.41,138.23,135.24,135.09,134.47,133.95,133.19,131.76,131.74, 131.62,131.51,131.18,130.81,130.77,130.06,129.56,127.22,127.11, 125.54,125.46,122.54,119.90,118.68,118.21,117.44,116.93,112.73,97.83,97.63,69.44,69.41,69.34,64.45,64.43,62.13,61.50,61.40,6 1.32,52.53,49.02,47.17,43.07,43.03,39.23,31.43,29.70,29.00,28.45,28.41,26.30,26.16,26.13,26.09,22.76,16.18,15.50,15.48,14.13.
[0387] Example 31 Synthesis of Compound CJ-C8-B1
[0388]
[0389] CJ-C8-B1 was prepared using the same method as compound CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,8-octanediamine as raw materials. MS m / z: 977.65 [M+H] + . 1H NMR(600MHz,CDCl3)δ8.26(s,1H),7.77(s,1H),7.67(d,J=7.86Hz,1H),7.61(d,J=7.68Hz,1H),7.57(d,J=9.72Hz,1H),7.48(t,J=7.8Hz,1H),7.36(t,J=4.2Hz,1H),7.22(d,J=4.32Hz,1H),7.05(s,1H),6.93-6.90(m,2H),6.82(d,J=1.86Hz,1H),6.77(dd,J=8.22,1.92Hz,1H),6.71(dd,J=8.28,1.5Hz,1H),6.51(s,1H),5.12(s,2H),5.00(s,2H),4.92(dd,J=12.36,5.34Hz,1H),4.31(s,4H),3.94(d,J=6.9Hz,1H),3.86(d,J=10.38Hz,1H),3.80-3.77(m,1H),3.54(s,1H),3.17(t,J=6.78Hz,3H),2.87-2.70(m,3H),2.23(s,3H),2.16(s,3H),2.11-2.09(m,1H),1.63-1.58(m,2H),1.41-1.35(m,4H),1.31-1.25(m,8H)。 13 CNMR(151MHz,CDCl3)δ171.24,168.77,168.75,168.09,167.43,166.81,157.83,155.43,153.85,143.06,142.68,142.34,138.32,135.15,135.13,134.57,133.96,132.95,131.77,131.57,130.77,130.06,129.58,127.14,125.54,122.55,119.89,118.62,118.22,117.81,116.93,116.11,112.82,106.15,97.73,69.41,69.39,64.47,64.44,62.41,62.39,61.97,49.05,47.37,47.32,43.38,39.33,31.94,31.44,29.70,29.37,29.28,28.88,28.86,28.76,28.74,28.66,28.63,26.58,26.55,26.47,26.45,22.77,16.18,15.51,14.13。
[0390] Example 32 Compound CJ-C 10 Synthesis of -B1
[0391]
[0392] CJ-C was prepared by the same method as compound CL-C3-B1 using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and N-tert-butyloxycarbonyl-1,10-decanediamine as raw materials. 10 -B1. MS m / z: 1005.70 [M+H] + . 1 HNMR (600MHz, CDCl3) δ8.25 (s, 1H), 7.77 (s, 1H), 7.67 (d, J = 7.8Hz, 1H), 7.61-7. 56(m,2H),7.49(t,J=7.74Hz,2H),7.36(t,J=4.08Hz,1H),7.22(d,J=4.92Hz,1H ),7.05(s,1H),6.94-6.90(m,2H),6.82(d,J=1.98Hz,1H),6.78(dd,J=8.22,2.0 4Hz,1H),6.72(dd,J=8.28,1.8Hz,1H),6.51(s,1H),5.12(s,2H),5.00(s,2H),4 .92(dd,J=12.36,5.28Hz,1H),4.31(s,4H),3.96(dd,J=22.26,12.78Hz,2H),3. 86(dd,J=11.52,4.08Hz,1H),3.79-3.77(m,1H),3.52(s,1H),3.19(t,J=6.96Hz ,2H),3.15-3.14(m,1H),2.87-2.72(m,3H),2.24(s,3H),2.17(s,3H),2.12-2.0 8(m,1H),1.65-1.60(m,2H),1.41-1.36(m,7H),1.30-1.29(m,5H),1.11(s,5H). 13C NMR (151MHz, CDCl3) δ171.23,169.98,168.71,168.04,167.44,166.74,157.81,155.41,153.83,143.07,142.68,142.34,138.33,135 .16,135.14,134.62,133.96,132.94,131.76,131.55,130.74,130.06,129.59,127.15,125.55,122.55,119.90,118.61,118.22,117 .91,116.93,116.13,112.83,106.15,97.75,69.40,64.46,64.44,62.41,62.39,62.03,59.53,49.04,47.40,47.36,43.42,39.42,38.15,31.93,31.44,31.25,29.70,29.66,29.37,29.32,29.11,28.96,28.94,28.80,26.79,26.69,22.78,22.70,16.18,15.51,14.13.
[0393] Example 33 Synthesis of Compound CL-P1-B1
[0394] (1) Synthesis of compound CL-P1-Boc
[0395]
[0396] 3-(2,6-Dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (500 mg, 1.81 mmol), tert-butyl [2-(2-aminoethoxy)ethyl]carbamate (443.71 mg, 2.17 mmol), cesium carbonate (886.23 mg, 2.72 mmol) were dissolved in N,N-dimethylformamide solution (5 ml) and stirred at room temperature for 8 h. The mixture was cooled to room temperature, the solvent was removed under reduced pressure, and water was added to dilute the mixture. The mixture was extracted with dichloromethane, and the organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain CL-P1-Boc (354 mg, 42.50%) as a yellow powder. MS m / z: 483.2 [M+Na] + .
[0397] (2) Synthesis of compound CL-P1
[0398]
[0399] CL-P1-Boc (354 mg, 0.77 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL) and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give CL-P1 (274.31 mg, 99%), a yellow liquid, MS m / z: 361.2 [M+H] + .
[0400] (3) Synthesis of CL-P1-B1
[0401]
[0402] CL-P1 (200 mg, 0.56 mmol), BMS-1001 (274.95 mg, 0.46 mmol), N,N-dimethylaminopyridine (113.46 mg, 0.93 mmol), EDCI (106.44 mg, 0.56 mmol) were added to N,N-dimethylformamide (5 ml) and stirred at room temperature for 4 h. The reaction mixture was diluted with water, extracted with dichloromethane, and the organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography to obtain CL-P1-B1 (20 mg, 3.85%), yellow powder, MS m / z: 937.55 [M+H] + . 1H NMR(600MHz,CDCl3)δ8.22(s,1H),7.82(s,1H),7.69(d,J=7.8Hz,1H),7.60(d,J=7.56Hz,1H),7.52-7.46(m,2H),7.33-7.32(m,1H),7.22-7.21(m,2H),7.13-7.10(m,2H),6.92(d,J=8.22Hz,1H),6.88(dd,J=8.52,2.04Hz,1H),6.81(d,J=1.98Hz,1H),6.77(dd,J=8.22,2.04Hz,1H),6.57-6.49(m,1H),6.46(s,1H),5.19-5.11(m,2H),5.07-5.01(m,1H),4.98(s,2H),4.31(s,4H),4.25(dd,J=37.32,12.66Hz,1H),4.08-3.97(m,3H),3.91-3.86(m,2H),3.82-3.80(m,1H),3.73-3.68(m,1H),3.64-3.54(m,3H),3.43-3.38(m,3H),2.83-2.66(m,3H),2.22(d,J=1.62Hz,3H),2.05(d,J=7.5Hz,3H),1.25(s,3H)。 13C NMR (151MHz, CDCl3) δ171.73,171.68,170.46,170.12,169.73,169.48,167.51,167.44,1 66.69,158.49,155.82,155.80,146.71,146.66,143.08,142.69,142.36,138.11,138.09, 136.50,136.40,135.10,135.02,135.00,133.98,133.82,133.74,132.43,131.79,131.75,131.71,130.99,130.10,129.56,129.51,127.12,127.10,125.55,124.83,122.54,119.9 3,119.89,118.70,118.67,118.22,116.94,116.89,116.86,112.80,112.75,112.04,112.00,110.27,110.18,97.35,97.34,69.59,69.52,69.28,69.26,68.46,68.33,64.47,64.4 4,62.56,62.38,61.30,61.25,49.10,49.07,48.94,47.47,47.35,41.89,41.82,39.65,39.60,31.94,31.48,31.35,29.71,29.38,23.07,22.71,22.65,16.16,15.38,15.37,14.14.
[0403] Example 34 Synthesis of Compound CL-P2-B1
[0404]
[0405] CL-P2-B1 was prepared by the same method as compound CL-P1-B1. MS m / z: 981.65 [M+H] + . 1HNMR(600MHz,CDCl3)δ8.18(s,1H),7.77(d,J=5.58Hz,1H),7.67(d,J=7.74Hz,1H),7.63-7.62(m,1H),7.60-7.58(m,1H),7.49-7.46(m,2H),7.35(t,J=4.08Hz,1H),7.22-7.21(m,2H),7.09-7.08(m,2H),6.92(d,J=8.22Hz,1H),6.88(d,J=8.58Hz,1H),6.82(s,1H),6.78(dd,J=8.22,1.5Hz,1H),6.52-6.50(m,2H),5.14-5.13(m,2H),5.01(s,2H),4.91-4.87(m,1H),4.31(s,4H),4.10(dd,J=12.9,7.8Hz,1H),4.04(dd,J=12.72,2.22Hz,1H),3.91-3.90(m,1H),3.71-3.67(m,3H),3.63-3.62(m,4H),3.53-3.52(m,2H),3.46-3.42(m,3H),3.37-3.33(m,1H),2.82(dd,J=12.96,2.76Hz,1H),2.70-2.68(m,2H),2.23(d,J=1.74Hz,3H),2.14(s,3H),2.11-2.07(m,1H),1.25(s,3H)。 13 C NMR(151MHz,CDCl3)δ171.81 , 171.74 , 169.58 , 169.55 , 169.45 , 169.43 , 168.79 , 167.57 , 167.55 ,165.78,158.29,158.26,155.60,155.56,146.72,143.07,142.67,142.34,138.20,136.19,136.16,135.16,135.10,134.01,133.39,132.51,131.76,131.67 ,130.85,130.07,129.57,127.17,125.55,124.83,122.68,122.56,120.00,119.97,118.65,118.23,116.92,116.85,116.82,112.76,111.76,110.26,110.21 ,97.60,70.73,70.60,70.13,70.11,69.44,69.43,69.39,69.37,69.34,69.11,69.05,64.46,64.44,61.88,61.02,60.90,48.89,48.85,47.06,47.01,43.96 ,42.21,42.17,39.67,39.64,38.47,38.15,31.93,31.35,31.30,31.24,29.71,29.67,29.37,29.33,22.96,22.70,21.55,19.77,19.51,16.18,15.45,14.13.
[0406] Example 35 Synthesis of Compound CL-P3-B1
[0407]
[0408] CL-P3-B1 was prepared by the same method as compound CL-P1-B1. MS m / z: 1025.30 [M+H] + . 1HNMR(600MHz,CDCl3)δ8.23(s,1H),7.77-7.74(m,2H),7.68(d,J=7.86Hz,1H),7.59(d,J=7.62Hz,1H),7.49(dd,J=15,7.68Hz,2H),7.36(t,J=4.14Hz,1H),7.22(d,J=4.02Hz,2H),7.09-7.06(m,2H),6.92(d,J=8.22Hz,1H),6.89(d,J=8.58Hz,1H),6.82(d,J=1.98Hz,1H),6.78(dd,J=8.22,2.04Hz,1H),6.51(s,2H),5.14(s,2H),5.01(s,2H),4.90(q,J=31.2,13.02Hz,1H),4.31(s,4H),4.09-4.02(m,2H),3.92-3.88(m,2H),3.70(t,J=4.92Hz,3H),3.64(s,4H),3.62-3.61(m,2H),3.57-3.56(m,2H),3.49(t,J=5.34Hz,2H),3.44-3.42(m,3H),3.34-3.30(m,1H),2.82(d,J=13.2Hz,1H),2.73-2.68(m,2H),2.23(s,3H),2.15(s,3H),2.09-2.07(m,1H)。 13C NMR (151MHz, CDCl3) δ171.77,169.36,169.23,168.64,167.62,166.82,158.30,155.61,155.60,146.77,146.75,143.07,142.66,14 2.33,138.20,136.10,135.15,135.10,134.00,133.41,133.39,132.48,131.76,131.67,130.84,130.06,129.57,127.17,125.54,12 2.56,119.97,118.65,118.23,116.91,116.86,112.73,111.65,110.19,97.60,70.68,70.65,70.55,70.53,70.38,70.14,69.42,69.35,69.24,69.20,69.17,64.45,64.43,61.97,61.88,61.04,48.85,47.04,47.03,42.29,39.49,31.37,29.70,22.83,16.18,15.46.
[0409] Example 36 Synthesis of Compound CL-P4-B1
[0410]
[0411] CL-P4-B1 was prepared by the same method as compound CL-P1-B1. MS m / z: 1070 [M+H] + . 1H NMR(600MHz,CDCl3)δ7.81(t,J=4.8Hz,1H),7.77(s,1H),7.69(d,J=7.74Hz,1H),7.60(d,J=7.68Hz,1H),7.50(q,J=15.3,7.56Hz,2H),7.37(t,J=3.48Hz,1H),7.23-7.22(m,2H),7.08-7.07(m,2H),6.92-6.88(m,2H),6.82(d,J=1.8Hz,1H),6.78(dd,J=8.22,1.86Hz,1H),6.51(s,2H),5.13(s,2H),5.01(s,2H),4.90-4.86(m,1H),4.31(s,4H),3.96(s,1H),3.85(t,J=5.22Hz,2H),3.71(q,J=7.5,5.1Hz,2H),3.65-3.64(m,7H),3.62-3.58(m,7H),3.52-3.51(m,2H),3.45(q,J=9.3,4.44Hz,2H),3.40(q,J=9.9,4.8Hz,2H),2.83(d,J=13.26Hz,1H),2.72-2.65(m,2H),2.24(s,3H),2.16(d,J=1.56Hz,3H),2.10-2.07(m,1H)。 13C NMR (151MHz, CDCl3) δ171.62,169.78,169.31,169.05,168.97,167.63,1 67.33,157.92,157.89,155.47,146.79,146.77,143.06,142.66,142.32, 138.34,136.10,135.18,135.17,134.01,133.13,132.50,132.49,131.7 3,131.64,130.82,130.04,129.56,127.19,125.54,124.82,122.56,119. 87,119.84,118.65,118.23,116.91,116.87,116.83,112.75,111.65,110.24,110.21,97.72,70.69,70.51,70.40,70.38,70.35,70.31,70.11,69 .43,69.38,69.36,69.29,64.46,64.43,62.27,61.66,61.63,48.85,47.21,42.27,39.28,39.26,31.37,31.25,29.70,22.83,22.81,16.18,15.49.
[0412] Example 37 Synthesis of Compound CL-S-B1
[0413] (1) Synthesis of compound CL-S-Boc
[0414]
[0415] 2-(2,6-Dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (500 mg, 1.81 mmol), cis-N-Boc-1,4-cyclohexanediamine (465.5 mg, 2.17 mmol), cesium carbonate (886.23 mg, 2.72 mmol) were dissolved in N,N-dimethylformamide solution (5 ml) and stirred at room temperature for 8 h. The mixture was cooled to room temperature, and the reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain CL-S-Boc (375 mg, 4.06%) as a yellow powder. MS m / z: 493.1 [M+Na] + .
[0416] (2) Preparation of compound CL-S
[0417]
[0418] CL-S-Boc (375 mg, 0.80 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL) and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give CL-S (292.29 mg, 99%) as a yellow powder. MS m / z: 371.1 [M+H] + .
[0419] (3) Synthesis of compound CL-S-B1
[0420]
[0421] CL-S (251 mg, 0.68 mmol), BMS-1001 (335.7 mg, 0.56 mmol), N,N-dimethylaminopyridine (114.3 mg, 1.13 mmol), EDCI (129.97 mg, 0.68 mmol) were added to N,N-dimethylformamide (5 ml) and stirred at room temperature for 4 h. The reaction mixture was diluted with water, extracted with dichloromethane, and the organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography to obtain CL-S-B1 (30 mg, 4.68%), a yellow powder. MS m / z: 947.45 [M+H] + . 1H NMR(600MHz,CDCl3)δ8.19(s,1H),7.81(s,1H),7.68(d,J=7.86Hz,1H),7.61-7.59(m,1H),7.49-7.42(m,2H),7.35-7.31(m,1H),7.22-7.20(m,2H),7.09(t,J=5.16Hz,1H),7.05(t,J=7.5Hz,1H),6.92(dd,J=8.22,4.68Hz,1H),6.84-6.80(m,2H),6.78-6.75(m,1H),6.50(d,J=3.6Hz,1H),6.41(dd,J=25.62,7.32Hz,1H),5.17-5.13(m,2H),5.01(d,J=16.56Hz,2H),4.93-4.89(m,1H),4.31(d,J=3.9Hz,4H),4.19(d,J=13.02Hz,1H),4.12(s,1H),4.03(d,J=12.84Hz,1H),3.89-3.82(m,2H),3.67-3.62(m,2H),3.53-3.49(m,1H),3.15(q,J=14.64,7.32Hz,1H),2.83-2.69(m,3H),2.23(d,J=12.42Hz,3H),2.15(d,J=6.84Hz,3H),1.82-1.81(m,2H),1.74-1.68(m,3H),1.45(s,2H),1.37(q,J=13.56,6.24Hz,1H),1.25(s,2H)。 13C NMR (151MHz, CDCl3) δ171.73,170.94,169.64,168.90,168.28,167.52,167.50,158.82,158.51,155.81,15 5.76,146.06,145.93,145.85,143.06,142.68,142.34,138.18,138.15,136.19,136.14,136.03,135.16,13 5.10,135.02,134.98,134.06,133.99,133.63,132.81,132.61,131.81,131.78,131.50,130.83,130.55,130.10,129.54,129.40,127.24,127.14,125.55,124.83,122.57,122.54,120.06,120.02,118.61,118.57,1 18.23,118.22,117.62,117.11,117.05,116.97,116.92,116.91,112.90,112.84,111.57,111.54,111.29,110.19,110.10,110.01,97.46,69.45,69.33,69.28,64.46,64.44,62.60,62.45,61.40,61.32,59.53,48.8 8,48.81,48.43,47.23,45.65,38.15,31.93,31.42,31.28,31.25,31.01,29.70,29.67,29.37,28.42,28.28,27.92,27.44,27.13,23.12,22.91,22.82,22.70,19.15,19.12,16.18,16.16,15.42,15.39,14.13,8.54.
[0422] Example 38 Synthesis of Compound CL-F-B1
[0423]
[0424] Compound CL-F-B1 was prepared using (2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and trans-N-Boc-1,4-cyclohexanediamine as raw materials by the same method as compound CL-S-B1. MS m / z: 947.65 [M+H] + . 1HNMR(600MHz,CDCl3)δ7.78(s,1H),7.66(dd,J=14.82,7.86Hz,2H),7.52-7.45(m,2H),7.40-7.37(m,2H),7.23-7.22(m,2H),7.08(d,J=7.08Hz,1H),7.02(s,1H),6.92(d,J=8.22Hz,1H),6.86(dd,J=8.58,3.78Hz,1H),6.82(d,J=1.98Hz,1H),6.78(dd,J=8.22,2.04Hz,1H),6.53(s,1H),6.14(d,J=7.86Hz,1H),5.12(s,2H),5.03(s,2H),4.91(dd,J=11.7,4.68Hz,1H),4.31(s,4H),3.78-3.72(m,3H),3.37-3.33(m,2H),2.90(d,J=16.32Hz,1H),2.80-2.69(m,2H),2.25(s,3H),2.19(s,3H),2.13-2.10(m,3H),2.01(s,2H),1.43(q,J=26.88,13.98Hz,2H),1.25(s,7H)。 13C NMR (151MHz, CDCl3) δ175.49,170.92,170.90,169.46,168.36,168.33,167. 52,157.31,155.21,145.94,143.07,142.68,142.37,138.49,136.14,135.2 4,135.15,134.01,132.64,132.47,131.75,131.45,130.72,130.08,129.92,129.89,129.56,127.23,125.55,124.83,122.55,119.85,118.62,118.22, 116.93,116.87,112.92,111.51,109.95,97.92,69.51,69.39,64.47,64.44,62.81,62.51,50.40,48.87,47.60,47.37,35.94,31.93,31.91,31.40,31. 35,31.28,29.78,29.70,29.66,29.62,29.61,29.56,29.53,29.49,29.37,29.35,29.33,29.25,27.22,25.55,25.37,22.81,22.70,16.21,15.57,14.13.
[0425] Example 39 Synthesis of Compound NC-C3-B1
[0426] (1) Synthesis of compound NC-C3-Boc
[0427]
[0428] Compound N-CRBN (500 mg, 1.89 mmol), N-tert-butyloxycarbonyl-1,3-propylenediamine (395.89 mg, 2.27 mmol), N,N-dimethylaminopyridine (489.45 mg, 4.84 mmol), EDCI (435.57 mg, 2.27 mmol) were added to N,N-dimethylformamide (5 ml) and stirred at room temperature for 4 h. The reaction mixture was diluted with 50 ml of water, extracted with 3×50 ml of dichloromethane, and the organic phase was washed with saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain NC-C3-Boc (652.41 mg, 82%) as a white solid. MS m / z: 443.1 [M+Na] + .
[0429] (2) Synthesis of compound NC-C3
[0430]
[0431] NC-C3-Boc (652.41 mg, 1.55 mmol) was added to a hydrochloric acid / 1,4-dioxane solution (4 M, 5 mL) and stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure to give NC-C3 (487.21 mg, 98%) as a white powder. MS m / z: 321.1 [M+H] + .
[0432] (3) Synthesis of compound NC-C3-B1
[0433]
[0434] NC-C3 (134 mg, 0.42 mmol), BMS-1001 (207.24 mg, 0.35 mmol), N, N-dimethylaminopyridine (70.55 mg, 0.70 mmol), EDCI (80.22 mg, 0.42 mmol) were added to N, N-dimethylformamide (5 ml) and stirred at room temperature for 4 h. The reaction mixture was diluted with water, extracted with dichloromethane, and the organic phase was washed with a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative high performance liquid chromatography to obtain NC-C3-B1 (35 mg, 9.33%), a white powder, MS m / z: 897.55 [M+H] + . 1H NMR(600MHz, CDCl3)δ8.78(s,1H),8.22(s,1H),7.82-7.79(m,2H),7.65(d, J=7.8Hz,1H),7.58(d,J=7.74Hz,1H),7.46(t,J=7.74Hz,1H),7.34(t,J=4.4 4Hz,1H),7.21(d,J=4.38Hz,1H),7.17(d,J=8.7Hz,1H),7.06(s,2H),6.93-6 .89(m,3H),6.80(d,J=1.98Hz,1H),6.76(dd,J=8.22,2.04Hz,1H),6.51(s,1 H),5.16(q,J=19.44,12.6Hz,2H),5.00(s,2H),4.46(s,1H),4.30(s,4H),4 .11(dd,J=35.4,12.84Hz,2H),3.90(d,J=8.88Hz,1H),3.80(s,1H),3.75(t, J=6.72Hz,2H),3.24(d,J=5.22Hz,2H),3.08-2.98(m,2H),2.77(t,J=6.6Hz, 2H),2.22(s,3H),2.13(s,3H),2.01(s,1H),1.57-1.51(m,2H),1.25(s,2H). 13 C NMR (151MHz, CDCl3) δ168.87,167.63,165.57,157.53,154.96,154.67,151.70,142.05,141.66,141 .33,137.06,134.07,133.98,133.93,132.96,132.47,130.78,130.62,129.84,129.07,128.53,126 .12,126.00,124.54,121.52,118.94,117.67,117.19,115.91,114.33,111.72,96.49,68.43,68.31,66.40,63.43,63.41,60.74,59.92,45.95,44.40,35.55,34.61,30.23,28.68,28.04,15.17,14.48.
[0435] Example 40 Synthesis of Compound NC-C5-B1
[0436]
[0437] NC-C5-B1 was prepared using the same method as NC-C3-B1 using compounds N-CRBN and N-tert-butyloxycarbonyl-1,5-pentanediamine as raw materials. MS m / z: 925.7 [M+H] + . 1 H NMR (600MHz, CDCl3) δ8.22(s,1H),7.79(s,1H),7.67(d,J=7.8Hz,1H),7.58(d,J=7.38Hz,1H),7.47(t,J=7.68Hz,1H),7.34(t,J=4.2Hz ,1H),7.21-7.18(m,4H),7.07(s,1H),6.91(t,J=6.12Hz,3H),6.80(d,J=1.74Hz,1H),6.76(dd,J=8.16,1.62Hz,2H),6.51(s,1H),5.15( s,2H),4.99(s,2H),4.44(s,2H),4.30(s,4H),4.11(q,J=34.62,12.72Hz,2H),3.90(d,J=7.02Hz,1H),3.78(dd,J=11.4,4.62Hz,4H),3. 27(d,J=5.58Hz,2H),3.11-3.02(m,2H),2.77(t,J=6.54Hz,2H),2.22(s,3H),2.13(s,3H),1.46-1.36(m,5H),1.25(s,1H),1.17(s,2H). 13 C NMR (151 MHz, CDCl3) δ 167.41 , 157.56 , 154.95,154.71,151.52,142.05,141.66,141.32,137.09,134.06,134.04,133.97,132.93,130.77,130.67,129.85,129.06,128.55,126.07,125.96,124.53,121.52,11 8.93,117.65,117.19,115.91,114.26,111.72,96.49,68.44,68.28,66.48,63.43,63.41,44.47,38.47,37.49,30.24,28.68,28.64,27.70,27.36,22.56,15.16,14.48.
[0438] Example 41 Synthesis of Compound NC-C6-B1
[0439]
[0440] NC-C6-B1 was prepared using the same method as NC-C3-B1 using compounds N-CRBN and N-tert-butyloxycarbonyl-1,6-hexanediamine as raw materials. MS m / z: 939.85 [M+H] + . 1 H NMR (600MHz, CDCl3) δ8.24(s,1H),7.78(s,1H),7.67(d,J=7.68Hz,1H),7.60-7.57(m,2H),7.47(t,J=7.68Hz,1H),7.34(t,J=4.14Hz,1 H),7.20(t,J=4.62Hz,4H),7.06(s,1H),6.91(t,J=7.14Hz,3H),6.80(d,J=1.8Hz,1H),6.76(dd,J=8.22,1.8Hz,1H),6.67(t,J=5.4Hz, 1H),6.51(s,1H),5.14(s,2H),4.99(s,2H),4.45(s,2H),4.30(s,4H),4.09(q,J=34.2,12.78Hz,1H),3.92(d,J=8.88Hz,1H),3.80-3.7 4(m,4H),3.28(d,J=5.88Hz,2H),3.09(m,2H),2.77(t,J=6.6Hz,2H),2.22(s,3H),2.13(s,3H),1.46(s,2H),1.33(s,2H),1.20(s,4H). 13 C NMR (151MHz, CDCl3) δ167.26,154.97,151.46,142.06,141.66,141.33,137.14,134.14,1 34.07,134.01,132.93,130.77,130.65,129.81,129.05,128.56,126.07,125.90,124.53, 121.52,118.90,117.63,117.19,115.91,114.24,111.73,96.55,68.44,68.30,66.60,63.43,63.41,44.51,38.29,37.53,30.27,28.68,27.89,27.80,24.81,24.80,15.16,14.48.
[0441] Example 42 Synthesis of Compound NC-C8-B1
[0442]
[0443] NC-C8-B1 was prepared using the same method as NC-C3-B1 using compounds N-CRBN and N-tert-butyloxycarbonyl-1,8-octanediamine as raw materials. MS m / z: 967.60 [M+H] + . 1 H NMR (600MHz, CDCl3) δ8.20(s,1H),7.78(s,1H),7.68(d,J=7.74Hz,1H),7.59(d,J=7.68Hz,1H),7.47(t,J=7.74Hz,1H),7.34(t,J=4.44Hz,1H),7. 22-7.20(m,4H),7.07(s,1H),6.93-6.90(m,3H),6.81(d,J=1.92Hz,1H), 6.76(dd,J=8.22,1.92Hz,1H),6.66(t,J=5.7Hz,1H),6.51(s,1H),5.16( s,2H),4.99(s,2H),4.44(s,2H),4.30(s,4H),4.13(q,J=40.8,12.84Hz, 2H),3.93(d,J=7.2Hz,1H),3.78(t,J=6.78Hz,4H),3.31(q,J=12.9,6.54 Hz,2H),3.16-3.08(m,2H),2.79(t,J=6.66Hz,2H),2.22(s,3H),2.14(s, 3H),2.00(s,1H),1.48(t,J=5.76Hz,2H),1.38(s,2H),1.25-1.21(m,9H). 13 C NMR (151MHz, CDCl3) δ168.83,167.07,165.27,157.59,154.91,154.68,151.32,142.06,141.66,141.32 ,137.06,134.14,134.06,133.96,132.91,132.43,130.79,130.67,129.82,129.05,128.58,126.06,125 .86,124.53,123.80,121.52,119.01,117.60,117.19,115.91,114.31,111.76,96.50,68.46,68.29,66.60,63.43,63.41,44.44,38.67,37.99,30.28,28.68,28.11,27.90,27.74,27.66,25.37,15.16,14.47.
[0444] Example 43 Compound NC-C 10 Synthesis of -B1
[0445]
[0446] NC-C3-B1 was prepared by using the same method as compound NC-C3-B1 with compounds N-CRBN and N-tert-butyloxycarbonyl-1,10-decanediamine as raw materials. 10 -B1. MS m / z:995.70[M+H] + . 1 H NMR (600MHz, CDCl3) δ8.19(s,1H),7.78(s,1H),7.68(d,J=7.74Hz,1H),7.60-7.57(m,2H),7.48(t,J=7.74Hz,1H),7.34(t,J=4.44Hz,1H),7.24- 7.21(m,4H),7.06(s,1H),6.94(dd,J=16.92,8.88Hz,3H),6.81(d,J=1.98Hz,1H),6.77(dd,J=8.16,1.92Hz,1H),6.61(t,J=5.82Hz,1H),6.50(s ,1H),5.15(s,2H),4.99(s,2H),4.46(s,2H),4.30(s,4H),4.10(q,J=39 .78,12.84Hz,2H),3.93(d,J=8.52Hz,1H),3.80(t,J=6.66Hz,4H),3.33( q,J=13.08,6.66Hz,2H),3.12(s,2H),2.80(t,J=6.66Hz,2H),2.22(s,3 H), 2.15 (s, 3H), 1.51 (t, J = 6.6Hz, 2H), 1.38 (s, 2H), 1.26-1.22 (m, 14H). 13C NMR (151MHz, CDCl3) δ168.66,166.87,164.82,157.45,154.87,154.61,151.21,142.06,141.67,141.33,137.08, 134.17,134.08,133.98,132.91,132.33,130.80,130.65,129.81,129.06,128.59,126.07,125.84,124.53,123. 81,121.52,119.03,117.57,117.20,115.91,114.33,111.81,96.54,68.47,68.31,66.62,63.44,63.41,61.04,60.20,46.27,44.44,38.72,38.05,30.32,28.68,28.16,28.10,28.03,27.93,27.87,25.65,25.56,15.15,14.46.
[0447] Example 44 Compound NC-C 12 Synthesis of -B1
[0448]
[0449] NC-C3-B1 was prepared by using the same method as compound NC-C3-B1 with compounds N-CRBN and N-tert-butyloxycarbonyl-1,12-dodecanediamine as raw materials. 12 -B1. MS m / z: 1023.95 [M+H] + . 11H NMR (600 MHz, CDCl3) δ 8.23 (s, 1H), 7.77 (s, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 7.62 Hz, 1H), 7.55 (t, J = 4.62 Hz, 1H), 7.49 (t, J = 7.74 Hz, 1H), 7.35 (t, J = 4.32 Hz, 1H), 7.24 - 7.21 (m, 4H), 7.05 (s, 1H), 6.95 (dd, J = 18.06, 8.94 Hz, 3H), 6.81 (d, J = 1.86 Hz, 1H), 6.77 (dd, J = 8.22, 1.92 Hz, 1H), 6.59 (t, J = 5.64 Hz, 1H), 6.50 (s, 1H), 5.14 (s, 2H), 5.00 (s, 2H), 4.47 (s, 2H), 4.31 (s, 4H), 4.04 (d, J = 12.84 Hz, 1H), 3.98 (d, J = 12.78 Hz, 1H), 3.90 (dd, J = 11.64, 3.84 Hz, 1H), 3.81 (t, J = 6.6 Hz, 3H), 3.66 (s, 1H), 3.34 (q, J = 13.2, 6.72 Hz, 2H), 3.14 (d, J = 5.88 Hz, 2H), 2.81 (t, J = 6.66 Hz, 2H), 2.23 (s, 3H), 2.16 (s, 3H), 1.53 (t, J = 6.72 Hz, 2H), 1.39 (s, 2H), 1.28 - 1.22 (m, 18H). 13 13C NMR (151 MHz, CDCl3) δ 169.63, 167.81, 166.61, 155.87, 155.54, 152.19, 143.07, 142.68, 142.34, 138.21, 135.21, 135.12, 135.07, 133.93, 133.18, 131.79, 131.60, 130.77, 130.06, 129.59, 127.11, 126.84, 125.55, 122.54, 119.96, 118.59, 118.22, 116.92, 115.35, 112.83, 97.63, 69.45, 69.36, 67.64, 64.46, 64.43, 62.24, 61.53, 47.25, 45.47, 39.67, 39.09, 31.36, 29.39, 29.36, 29.32, 29.29, 29.27, 29.25, 29.14, 29.03, 26.82, 26.80, 26.75, 26.68, 16.17, 15.49.
[0450] Example 45
[0451] Instruments: 96-well plate, low-temperature centrifuge, metal bath, shaker, microplate reader, SDS-PAGE gel electrophoresis instrument, gel imager
[0452] Reagents: RIPA lysis buffer, PMSF protease inhibitor, 1.5ml centrifuge tube, BCA protein kit, Tris-Mops-SDS Running Buffer Powder, BeyoColor TM Color pre-stained protein, PVDF membrane, rapid transfer solution, TBST, protein-free rapid blocking solution, PD-L1 antibody, GAPDH antibody, horseradish peroxidase-labeled goat anti-mouse IgG (H+L), ECL luminescent solution
[0453] Cell line: MC38 cells
[0454] Western blot assay to detect the degradation activity of the above compounds on PD-L1 protein
[0455] Mouse colon cancer cells MC38 were grown in complete DMEM medium at 37°C and 5% CO2. Cells (2 x 10 5 After incubation for 12 h, complete medium containing 5 μM of the test compound was added to each well and incubated for a further 24 h.
[0456] After washing MC38 cells twice with PBS, digest and centrifuge them, place them in a pre-cooled homogenate tube, add protease inhibitors (PMSF) and RAPI lysis buffer (1:100, v / v), and lyse them on ice for 30 minutes. After lysis is completed, centrifuge at 12000rpm for 15 minutes at 4°C. After centrifugation, take the supernatant and place it in a pre-cooled centrifuge tube. Subsequently, the concentration of the protein extract was measured using the BCA quantitative kit, and the corresponding loading volume of 20μg protein was calculated. The protein was separated by electrophoresis using SDS-PAGE, and the gel containing the target protein was cut according to the position of the protein marker after the electrophoresis. The protein band was transferred to the PVDF membrane by semi-dry transfer. The PVDF membrane was placed in an antibody incubation box, washed briefly with TBST, and then a protein-free rapid blocking solution was added, and the membrane was shaken on a shaker for 30 minutes. After blocking, the PVDF membrane was washed 4 to 5 times with TBST, each time for 10 minutes. Subsequently, the PD-L1 antibody diluent was added, and the bands were incubated overnight at 4°C. The PVDF membrane was washed with TBST 4-5 times, 10 min each time, and the bands were incubated with horseradish peroxidase-labeled goat anti-mouse IgG (H+L) dilution at room temperature for 2 hours. The gel was developed with ECL chemiluminescent solution in a gel imager, observed and photographed. Finally, the grayscale analysis and quantification of the protein bands were performed using ImageJ software and GraphPad Prism 10.1.2 software.
[0457] As can be seen from the above, most of the compounds based on the design, synthesis and activity study of PD-L1 PROTAC in the present invention show certain degradation. The PROTAC with VHL-B as the E3 ligase ligand is overall better than the PROTAC molecule with VHL-A as the E3 ligase ligand. It can be further seen from the results of the accompanying drawings that when the linker adopts a cyclohexane rigid chain, the conformation of the linkr is different, and the resulting PROTAC compound has a very different degradation effect on the PD-L1 protein. It can be seen from the overall degradation effect that the PROTAC of the CRBN series in this patent has a better degradation effect than the VHL series. Among them, the compound with the best degradation effect is CL-F-B1, with a degradation effect of 67.55%.
Claims
1. A protein degradation targeting chimera, characterized in that: The protein degradation targeting chimera is a compound composed of a target protein ligand, an E3 ligase ligand and a linker and a pharmaceutically acceptable salt thereof. The specific structure of the compound is shown in Formula 1: Wherein, part A is selected from structural fragments VHL-A, VHL-B, CRBN, N-CRBN, and their structures are shown below: Among them, linker is selected from n1 is an integer from 3 to 12; n2 is an integer from 0 to 5.
2. The protein degradation targeting chimera according to claim 1, characterized in that: The protein degradation targeting chimera is a compound represented by Formula 1 and a pharmaceutically acceptable salt thereof, Wherein, part A is selected from structural fragments VHL-A, VHL-B, CRBN, N-CRBN, and their structures are shown below: In the formula, linker is selected from n1 is 3, 4, 5, 6, 7, 8, 10 or 12; n2 is 0, 1, 2, 3 or 4.
3. The protein degradation targeting chimera according to claim 2, characterized in that: The protein degradation targeting chimera is the following compound and a pharmaceutically acceptable salt thereof, 4. An application of the protein degradation targeting chimera according to claim 1, characterized in that: The protein degradation targeting chimera and its salt are used for protein degradation targeting PD-L1.
5. The use of the protein degradation targeting chimera according to claim 4, characterized in that: Use of the protein degradation targeting chimera and its salt in preparing drugs for treating PD-L1 protein related diseases.
6. The use of the protein degradation targeting chimera according to claim 5, characterized in that: The PD-L1 protein-related disease is a tumor or other PD-L1 protein-related disease.
7. The use of the protein degradation targeting chimera according to claim 6, characterized in that: The tumor is colorectal cancer, lung cancer, melanoma, bladder cancer, head and neck squamous cell carcinoma, breast cancer, prostate cancer, kidney cancer, ovarian cancer, liver cancer, pancreatic cancer, multiple myeloma.
8. A pharmaceutical composition for treating PD-L1 protein-related diseases, characterized in that: The composition contains the protein degradation targeting chimera according to claim 1.
Citation Information
Cited By
Protein degradation targeting chimera of CPT1A as well as preparation method and application of protein degradation targeting chimera
CN120484053A
